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1. Introduction 
 
1.1. Adult subventricular zone and neural stem and precursor cells 
In adulthood, pools of neural stem cells persist in at least two brain regions: the sub-granular zone (SGZ) of 
the hippocampus and the sub-ventricular zone (SVZ) of the lateral ventricles. The SVZ is extensively 
investigated for the understanding of neurogenesis [Llorens-Bobadilla E., et al. (2017)] and its implications 
in hyperproliferative diseases such as brain tumors [Gollapalli K., et al. (2017)]. Indeed, Neural stem cells 
(NSCs) maintain their self-renewal capacity along with the ability to differentiate into neuronal and glial 
precursors depending on microenvironmental signals. In the developing brain, these precursors cells can 
give rise to neurons, astrocytes, and oligodendrocytes [Bergström T., et al. (2012)]. Neurons are the key 
impulse generating and propagating brain cells. They classically, arise from asymmetric division of NSCs, 
followed by lineage commitment through several stages of differentiation. Other possible sources, such as 
reprogramming of astrocytes, have also been described [Pino A. et al. (2017)]. Astrocytes are star-shaped 
components of the central nervous system (CNS) that represent about 50% of all brain cells. They participate 
in homeostatic distribution and clearance of metabolites [Villa G.R. et al., (2016)] and [Dossi, E. et al. 
(2017)], and control exchange at the blood brain barrier. In collaboration with Schwann cells and astrocytes, 
oligodendrocytes synthesize and integrate large amounts of lipids necessary to generate the myelin sheath 
of axons without which rapid propagation of neuronal impulses could not be carried out [Camargo N. et al. 
(2017)] and [Hofmann K. et al. (2017)]. In the adult CNS, small pools of NSCs are perpetuated. Under 
physiological and pathological conditions, they maintain neurogenic functions but also regulate brain 
homeostasis, express phagocytic functions towards microglia, and sense and dampen inflammatory signals 
[Martino G., et al. (2014)].                                                                                              
 
1.2. Cells of origin of gliomas 
Neural stem and precursor cells guarantee a backup pool of new neuronal and astroglial cells in the brain. 
Their function is capital to maintain CNS plasticity and rescue from potential neurodegenerative threats 
[Yamaguchi M. et al. (2016)]. However, failure to tightly control the mechanisms of their proliferation 
and/or differentiation can lead to accumulation of genetic alterations that promote malignant transformation 
and initiate glioma development. Gliomas and glioblastoma maintain many stem cell characteristics and a 
hypothesis of glioblastoma-cancer stem cell (GBM-CSC) has been proposed [Yuan X. et al. (2004)]. Pools 
of GBM-CSC share embryonic and NPC stem cell markers such as nestin, sex determining region Y-box2 
(SOX2), Krüppel-like factor 4 (KLF-4), myelocytomatosis cellular oncogene (c-Myc), CD44, CD133, and 
the astrocytic marker Glial fibrillary acidic protein (GFAP). Inhibition or silencing of these genes has shown 
positive effects against GBM growth in vitro and in vivo [Bradshaw A. et al. (2016)]. The role of GBM-
CSC (GSCs) is actively being investigated for therapeutic purposes to understand the genesis and 
maintenance of GBM aggressiveness and its resistance to therapy. Upon therapy, pools of GSCs may alter 
gene expression levels and metabolic features not targeted by an initial treatment. After therapy schedule, 
non-drug-sensitized cells, could generate new populations of GBM resistant to standard therapy [Liebelt B. 
D. et al. (2016)].  
 
1.3. Glioblastoma: clinical presentation and diagnostics 
1.3.1. Clinical presentation of glioblastoma 
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Patients with glioblastoma present a variety of neurological symptoms ranging from headache, nausea, 
vomiting, dizziness, seizures. The presented symptoms vary according to the location of the glioblastoma 
and the neurological centers that might be affected. [Hanif F. et al. (2017)]. 
1.3.2. Diagnosing glioblastoma 
Often, glioblastoma is diagnosed after the detection of the first neurological symptoms. The diagnosis of 
glioblastoma is a multi-step process. Neurological examination, brain imaging and biopsy are performed to 
confirm brain neoplasms. Multiple imaging techniques are available to diagnose glioblastoma. They include 
but are not limited to gadolinium-enhanced MRI, magnetic resonance spectroscopy, functional magnetic 
resonance imaging, FDG-PET [Szopa W. et al (2017)]. After diagnosis, multi-disciplinary decision will be 
taken for the coordination of maximal surgical resection and the schedule of chemo-radiotherapy. Many of 
the diagnostic techniques, such as functional fMRI and FDG-PET are also used to monitor the outcome of 
therapy on the GBM [Louis D. N. et al. (2016)]. 
1.4. Genetic diversity of glioblastoma 
Glioblastoma present multiple genetic alterations and have been classified into different subtypes: 
proneural, classical, mesenchymal [Brennan C. et al. (2013)] and [Figure 1.1]. Primary glioblastoma 
generally arises without an identified pre-existent lesion. A first level of classification is based on the 
isocitrate dehydrogenate (IDH) status segregating between IDHwt and IDHmu GBMs [Olar A. et al. (2014)] 
and [Louis D. N. et al. (2016)]. Heterogeneity of glioblastoma has always been a concern in the handling of 
patients and it has been associated with therapy failure and GBM recurrence. Inter-tumoral heterogeneity 
exists when comparing GBM in young (less than 18 years old) to older patients (more than 45 years old). 
Alterations in tumor protein 53 (TP53), platelet derived growth factor receptor alpha (PDGFRA), v-RAF 
murine sarcoma viral oncogene homolog B (BRAF) tended to be dominant in young patients whereas in 
older patients more frequent alterations were found in O (6)-methylguanine-DNA methyltransferase 
(MGMT) methylation status and phosphatase and tensin homolog (PTEN) [Ferguson S. D. et al. (2016)]. 
On top of this first level of heterogeneity, coexists a second level of intra-tumoral heterogeneity. For 
gliomas, intra-tumoral heterogeneity is associated with poor clinical outcome [Andor N. et al. (2016)]. 
Indeed, clones of a same tumor showing different genetic alterations can also show differential sensitivity 
to drug treatment and trigger resistance to therapy [Meyer M. et al. (2015)]. GBM intra-tumoral 
heterogeneity is not a fixed stage of the tumor as it evolves under therapy and phenomena of genetic subtype 
switches are commonly described along with some driver genes experiencing switches in codon point 
mutations of a same protein encoded gene such as epidermal growth factor receptor (EGFR), PDGFRA, 
TP53 [Wang J. et al. (2016)]. 
Figure 1.1 Genetic diversity of glioblastoma. GBMs are classified into three main genetic subtypes based 
on the loss or mutation of tumor suppressors and overexpression of oncogenes. The most common proneural 
GBMs often have loss or mutation in TP53 or cdkn2a, associated with overexpression of PDGFR. EGFR is 
one of the most amplified genes. 57% of GBMs show rearrangements, alternative splicing, mutation, or 
amplification in EGFR, associated with homozygous deletion of cdkn2a (Classical GBM) or dual 
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loss/mutation in TP53-PTEN (Mesenchymal GBMs). Another group of mesenchymal GBMs is enriched in 
concomitant alterations in NF1 and TP53. Adapted from [Brennan C. et al. (2013)]. 
 
1.5. The brain tumor microenvironment 
GBMs are highly proliferative tumors that need a supportive microenvironment.  Therefore, GBMs secrete 
factors that can modify and re-program surrounding brain cells [Treps L. et al. (2017)]. Microglia, which 
are resident brain macrophages, represent 5 to 20% of the total glial cells [Zhou W. et al. (2014)] and can 
account for up to 30% of the tumor mass. However, they are de-programmed from their M1-polarization 
and re-programmed to be M2-polarized [Arcuri C. et al. (2017)]. This functional phenotype is characterized 
by a panel of immunosuppressive/tumor-promotive cytokines (IL4, IL10, IL13) and decreased MHC-II 
expression leading to poor tumor antigen-presentation to dendritic cells [Gieryng A. et al. (2017)]. Tumor 
secreted reactive oxygen species (ROS) induce increased nuclear respiratory factor 2 (NRF2) expression in 
tumor associated dendritic cells leading to lack of maturation and impaired antigen presentation [Wang J. 
et al. (2017)]. Nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), which balances NRF2 
responses, is also altered in myeloid derived suppressor cells (MDSCs). In the micro-milieu of GBMs, 
canonical NFkB signaling of p50-p65, has been shown to be anti-inflammatory in MDSCs, and knocking 
out p65 in myeloid cells resulted in increased secretion of proinflammatory cytokines (IFNγ, TNFα), Th1 
polarization, and proliferation of CD8+ cytotoxic T cells [Achyut B. R. et al. (2017)]. Astrocytes are 
particularly enriched around GBM masses, where they secrete interleukin 6 (IL6), increase matrix 
metalloproteinase 14 (MMP14), and contribute to glioma migration [Chen et al. (2016)]. Knocking down 
connexin 43 in reactive astrocytes abolishes channel communication between GBM and astrocytes and 
significantly reduced GBM invasion in a syngeneic model of GL261 glioma [Sin W. C. et al (2016)]. 
 
1.6. Glioblastoma metabolism 
1.6.1. “Non-oncogene addiction” in cancer 
It is well accepted that oncogenesis occurs by progressive accumulation of a range of genetic alterations 
inducing hyperactivation of oncogenes often accompanied by inactivation of tumor suppressors [Tsatsanis 
C. et al. (2000)]. During these genetic changes, cells transitioning to a malignant lesion also experience 
changes in their metabolism to adapt to various levels of stress. Therefore, genetic, and epigenetic changes 
in genes not inherently tumorigenic also occur [Vivanco I. (2014)]. These modifications are defined as non-
oncogene addiction, where growing tumor cells learn to control metabolic pathways promoting their 
survival: Stress response transcription factors and their pathways, metabolite uptake, drug efflux, inhibition 
of death pathways [Nagel R. et al. (2016)]. 
1.6.2. Oxidative stress in glioblastoma 
High proliferative and metabolic rates in glioblastoma require increased mobilization of all cellular 
compartments especially those involved in energy production, de novo protein synthesis, and catabolism. 
Metabolic pathway by-products accumulate in the form of reactive oxygen and nitrogen species (ROS/NOS) 
[Salazar-Ramiro A. et al. (2016)].  Sites of ROS generation include mitochondria (mt), endoplasmic 
reticulum (ER), and peroxisomes [Holzerová E. et al. (2015)]. GBM-mitochondria preferentially generate 
adenosine triphosphate (ATP) using glycolysis over oxidative phosphorylation [Agnihotri S. et al. (2016)]. 
Modifications in the electron transport chain contribute to increased mitochondrial oxidative stress. One of 
the most important by-products of mitochondrial ATP production is ROS [Tan Q. et al. (2017)]. Increased 
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GBM metabolism requires increased protein synthesis and folding by the endoplasmic reticulum (ER). ER 
activity generates ROS itself, and in the context of heavy mitochondrial ROS and Ca2+, the ER faces 
exhaustion, and proper protein folding cannot be guaranteed [Sevier C. S. et al. (2008)]. This state of 
exhaustion is called ER stress and, in an effort to restore ER homeostasis, the unfolded protein response of 
the ER (UPRER) is engaged [Bhat T. A. et al. (2017)] and [Hempel N. et al. (2017)].  Depending on the 
nature of the stressor, its duration, and the timing of expression of sensor proteins, the UPRER can promote 
survival or death. Under ER stress, ER-resident nuclear respiratory factor 1 (NRF1) translocates to the 
nucleus and directs the expression of proteins of proteolytic cascades and antioxidant responses [Peñaranda 
Fajardo N. M. et al 2016)] and [Lindholm D. et al. (2017)]. As mitochondrial DNA (mtDNA) only encodes 
1% of mitochondrial proteins, alterations in ER-dependent protein folding during ER stress directly impact 
proteins destined to mitochondria. As in the ER, mtDNA encoded-proteins are subjected to quality control 
by mitochondrial chaperones [Raza M. H. et al. (2017)]. Sustained oxidative stress, mtDNA damage and 
increased misfolded proteins induce mitochondrial unfolded protein response (UPRmt) and mitochondrial 
retrograde signaling to the nucleus to mobilize the expression of quality control genes [Kenny T. C. et al. 
(2017)]. UPRmt is directly linked to UPRER as most of the requested quality control proteins are also ER 
stress dependent transcription factors such as activating transcription factor 5 (ATF5) and C/EBP 
homologous protein (CHOP) [Qureshi M. A. et al. (2017)]. Chronic and unbalanced ROS exposes to genetic 
and epigenetic alterations such as DNA damage, oxidation of lipids and proteins, all leading to the state 
called oxidative stress, where, oxidant-induced modifications alter the homeostatic function of cellular 
organelles and affect multiple networks. Targets of ROS include key signaling pathways such as Kelch-like 
ECH-associated protein1 (Keap1) / Nuclear factor erythroid 2-related factor 2 (NRF2), nuclear factor kappa-
light-chain-enhancer of activated B cells (NFkB), mitogen activated protein kinase (MAPK), 
phosphatidylinositol-4,5-bisphosphate 3 kinase (PI3K) / protein kinase B (AKT). ROS also interfere with 
ion homeostasis and thus impact multiple cellular reactions they run including receptor transporter functions 
in endo- and exocytosis [Zhang J. et al. (2016)] and [Prasad S. et al (2017)]. 
1.7. Antioxidant responses in GBM 
In cancer cells and glioblastoma, ROS levels have been described as high, and cellular antioxidant systems 
are mobilized but ineffective [Moloney J. N. et al. (2017)]. The master regulator of cellular antioxidant 
responses is NRF2 [Rinaldi M. et al. (2016)]. Under physiological conditions, NRF2 is mostly in the 
cytoplasm, where it is sequestered by Keap1 and regularly ubiquitinylated for proteasomal degradation [Zhu 
J. et al. (2014)]. Sustained oxidative insults induce NRF2 phosphorylation and its nuclear translocation 
where it binds ARE-DNA sequences to modulate the expression of antioxidant effectors and detoxification 
enzymes [Suzuki T., et al. (2017)]. However, in cancer cells, homeostatic regulation of ROS by NRF2 is 
disrupted. Indeed, oxidative stress repurposed proteins destabilize the Keap1-NRF2 complex either by 
competing with Keap1 for binding with NRF2 (p21) or competing with NRF2 for binding with Keap1 (p62, 
iASPP). Free NRF2 translocates in the nucleus and constitutively stimulates the transcription of genes 
encoding for proteins with cytoprotective functions. This explains why high NRF2 activity has been 
described in several cancers [Ge W. et al. (2017)].  
Under physiological conditions, the signaling of NRF2 pathway is balanced by multiple factors including 
NFkB [Figure 1.3]. NFkB represents a family of transcription factors with 5 subunits: 3 proteins with Rel 
homology domains Rel-a (p65), Rel-b, c-Rel, and 2 pre-proteins p100 and p105 which are cleaved to 
generate p50 and p52. These subunits form homo- and heterodimers, with the most common form being 
p50-p65 [Zhang Q. et al. (2017)]. In many cancers and in glioblastoma, NFkB is highly expressed and 
described as pro-inflammatory and pro-proliferative with the capacity to reprogram multiple cellular 
pathways [Cahill K. E. et al. (2016)] and [Friedmann-Morvinski D. et al. (2016)]. In GBMs, NFkB signaling 
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is modulated by multiple tumor associated proto-oncogenes and regulates major pathways promoting GBM 
survival by inhibiting Notch signaling, increasing B-cell lymphoma extra-large (Bcl-xL) and survivin, 
promoting angiogenesis and inflammation via pro-inflammatory cytokine secretion [Cahill K. E. et al. 
(2016)]. 
1.8. Standard therapy for glioblastoma 
Currently, multimodal therapy including surgery, radiotherapy and chemotherapy is the standard of care for 
glioblastoma patients. If the patient would not withstand a surgical intervention, stereotactic needle biopsy 
is performed to collect tumor specimens. Otherwise, surgery with craniotomy (standard or awake) is carried 
out [Hervey-Jumper S. L. et al. (2015)]. Using current imaging techniques, the surgeon can locate the tumor 
and perform maximal safe resection of the tumor mass [Li Y. M. et al. (2017)]. The extent of resection of 
GBM has been associated with increased patient survival in multiple studies, thus the importance to use all 
available tools (iMRI, fMRI, functional mapping…) to maximize tumor removal before chemo-radiotherapy 
[Brown T. J. et al. (2016)]. Radiotherapy is based on the ability of ionizing radiation to generate double 
strand breaks in DNA and promote cell death. Currently, common approaches for radiotherapy include, 
volumetric modulated arc therapy, hypofractionation, and intensity modulated radiotherapy coupled with 
image-guided radiotherapy. The aim is to deliver beamlets of different intensities to different regions of the 
tumor mass, while sparing unaffected brain [Aktan M. et al. (2015)] and [Macchia G. et al. (2017)]. More 
recently, hypofractionation radiation therapy, has gained more interest especially in elderly GBM patients 
with poor prognosis [Mak K. S. et al. (2017)]. It uses lower irradiation intensities while dividing the radiation 
schedule. Doing so, normal cells would have time to recover from therapy effects (less side-effects), while 
irradiated tumor cells that could be escaping radiation induced death, could be re-targeted with another 
round of radiation [Glaser S. M. et al. (2017] and [Gzell C. et al. (2017)]. Because of better survival 
outcomes, combination of radiotherapy with adjuvant chemotherapy is the standard of care after surgical 
resection [Davis M. E. (2016)] and [Kole A. J. et al. (2017)]. Temozolomide (TMZ) is the first-line 
chemotherapeutics prescribed in GBMs. It is an alkylating molecule introducing methyl groups in nucleic 
acids guanine (N7, O6) and adenine (N3). These modifications are detected by base excision repair and 
mismatch repair pathways that will induce cell cycle arrest and try to repair the DNA, but failure of repair 
will signal to death [Anjum K. et al. (2017)]. While TMZ therapy prolongs the survival of some GBM 
patients, more than half of them do not respond to the treatment. This is mainly due to hyperactivation of 
MGMT, which antagonizes TMZ action, by removing TMZ introduced O6-methyl groups on guanines. 
Indeed, GBM patient survival treated with TMZ, inversely correlates with MGMT activation levels, and 
methylation of MGMT promoter is considered a favorable biomarker to TMZ therapy [Stupp R. et al. 
(2005)] and [Taylor J. W. et al. (2015)]. Bevacizumab is usually used as second line of treatment. It is a 
monoclonal antibody against vascular endothelial growth factor (VEGF), and it acts by blocking VEGF-
induced angiogenic cascades that would be triggered in GBMs upon VEGF binding to its receptor (VEGFR) 
[Wang Y. et al. (2016)]. Bevacizumab is often combined with irinotecan, leading to important reported side-
effects (hypertension, anemia, deterioration of liver functions, pulmonary toxicity) [Kim J. H. et al. (2017)]. 
Since GBMs are highly heterogenous and adaptable tumors, they resist to standard multimodal therapy, re-
occur and are ultimately fatal. Development of new therapeutic strategies are urgently needed, targeting 
genetic and metabolic GBM addictions.   
 
1.9. Vanilloids, cannabinoids and cannabidiol 
Vanilloids were first discovered in capsicum annuum (chili pepper), a native plant of the Americas 
domesticated since 7500 B.C. and described in pre-columbian Aztec manuscripts [Perry L. et al. (2007)]. 
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The active ingredient capsaicin was isolated by Tresh in 1846, its chemical structure published in 1919, and 
the capsaicin induced vanilloid receptor VR1 described by Holzer in 1991. VR1 has been later renamed 
transient receptor potential vanilloid type 1 receptor (TRPV1) because of its structural similarity with 
members of the TRP channel superfamily [Nilius B. et al. (2007)]. In 1975, resiniferatoxin (RTX), a potent 
capsaicin analog, was isolated. Because they share a homo-vanillin group allowing their biological effects, 
capsaicin, RTX and their analogs are called vanilloids [Szallasi A. et al. (1999)]. Cannabinoids were 
originally so-called because of their first discovery as components of cannabis sativa plant [Figure 1.2]. 
Today, we understand that cannabinoids include the endocannabinoids (physiologically produced in the 
CNS), synthetic cannabinoids (chemically produced to mimic cannabinoid effects) and the 
phytocannabinoids (natural substances mainly from the cannabis sativa plant) [Russo E. B. (2016)], [Hanuš 
L. O. et al. (2016)], and [Turner S. E. et al. (2017)]. Endogenous cannabinoids have been shown to stimulate 
vanilloid receptors, and vice-versa. This led to the understanding that vanilloid- and cannabinoid receptors 
are part of a same G protein coupled receptor family [Zygmunt P. M. et al. (1999)]. Delta-9-tetra-
hydrocannabinol (∆9-THC) and cannabidiol (CBD) are the two most studied substances of cannabis sativa. 
To the contrary of ∆9-THC, CBD is a non-psychoactive substance with poor affinity to cannabinoid 
receptors [Falenski K. W. et al. (2009)]. Phytovanilloids as with endovanilloids are fatty acid-based 
molecules with capacity to modulate TRPV channels [Starowicz K. et al. (2007)]. CBD, as a lipophilic 
compound crosses the cellular plasma membrane and accesses a plethora of intracellular targets influencing 
mitochondrial calcium stores, glycine receptors, fatty amide hydrolase [Zhornitsky S. et al. (2012)]. The 
high lipophilicity of CBD allows it to cross the blood brain barrier giving it access to targets in the central 
nervous system [Cabral G. A. et al. (2014)]. Cannabidiol is being considered for the treatment of several 
disorders including epileptic seizures [Jones N. A. et al. (2010)], multiple sclerosis, chronic pain [Iskedjian 
M. et al. (2007)] and is an orphan drug for glioblastoma therapy [Dumitru C. A. et al. (2018)]. 
 
 
Figure 1.2 Cannabinoids as therapeutic agents. Illustration of the cannabis sativa L. plant and the 
chemical structures of extracts with medicinal interest:  Δ9-tetrahydrocannabinol (Δ9THC), cannabinol 
(CBN), cannabidiol (CBD), Δ8-tetrahydrocannabinol (Δ8 THC), cannabigerol (CBG), cannabichromene 
(CBC), tetrahydrocannabivarin (THCV), cannabivarin (CBV), cannabidivarin (CBDV). Adapted from 
[Russo E. B. (2016)], [Morales P. et al. (2017)].  
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1.10. Aim of the thesis  
Cannabidiol has been reported to have significant cytotoxicity effects in cultured GBM cells [Singer E. et 
al. (2015)]. Promising in vitro and pre-clinical studies have propelled this phyto-therapeutics to clinical 
trials for the treatment of GBMs [Massi P. et al. (2004)]. However, a reliable patient stratification scheme 
for beneficial CBD therapy is still missing. 
This PhD work aims to study the genetic diversity of human GBM in mouse and uncover potential genetic 
and metabolic alterations that could be used as predictive biomarkers of CBD sensitivity. 
 
Scientific questions are: 
1. Which cell death mode is induced in CBD sensitive GBMs? 
2. What is the impact of GBM genetic diversity on CBD induced therapy? 
3. Which molecular pathways are triggered in GBMs upon CBD treatment? 
4. Can patients be stratified for beneficial CBD therapy? 
2. Materials 
2.1. Table 2.1 Laboratory equipment. 
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2.2. Table 2.2 Consumables. 
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2.3. Table 2.3 Chemicals and reagents. 
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2.4. Table 2.4 Small molecules. 
 
 
2.5. Table 2.5 Collection of human GBMs 
 
 
Human primary GBMs were obtained by surgical resection of brain tumors after informed consent and 
following recommendations of respective institutional review boards of the operating hospitals. GBM cells 
labeled as “NCH” were obtained from a collaborating laboratory in Heidelberg [Campos B. et al. 2010].  
GBM cells labeled as Line# were obtained from a collaborating laboratory in Italy [Galli R. et al. 2004]. In 
both cases primary cells were obtained after enzymatic dissolution of tissues and by seeding in floating 
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neurosphere conditions. Primary tumor samples were classified as glioblastoma following the World Health 
Organization guidelines.  
The human cell line HEK-293T was obtained from ATCC. 
 
 
2.6. Cell culture media and supplements 
DMEM-10%FBS: DMEM (Biochrom, # FG0415), 10% FBS, 1% Pen/Strep 
NPC culture medium: DMEM-F12 (Gibco 11320-074 or 21041-033), 1% Pen/Strep, 10ng/ml EGF, 
10ng/ml FGF, 1x B27 (Invitrogen-17504-044) 
NSC medium: NeuroCult™ Basal Medium-Mouse (STEMCELL technologies cat#05700), NeuroCult™ 
proliferation supplement-Mouse (STEMCELL technologies cat#05701), 1% Pen/Strep, 10ng/ml EGF, 
10ng/ml FGF, heparin. 
 
2.7. Buffers and solutions 
• 1x PBS:  Apotheke, Klinikum Grosshadern 
• TBST permeabilization buffer: 3% donkey serum, 150mM Nacl, 1% Tween20,100mM Tris in 
1xPBS. 
• FACS buffer: 1% BSA, 2mM EDTA in 1x PBS (sterile filtered) 
• 5x TBE buffer: 54g trisbase, 27.5g borate, 20ml of 500mM EDTA (pH 8) in1L demineralized H2O. 
• 4% PFA: 40g paraformaldehyde (PFA) in 1000ml 
• Drug vehicle for in vivo i.p. injections: 2% EtOH, 2% tween80, 96% saline 
• Total protein isolation buffer: 96% RIPA buffer, 2% protease inhinitor (P8340-Sigma), 1% 
phosphatase inhibitor cocktail-1 (P5726-Sigma), 1% phosphatase inhibitor cocktail-3 (P0044-
Sigma) 
2.8. Table 2.6 List of kits for cell- and molecular biology 
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2.9. Table 2.7 List of plasmids 
 
 
2.10. Immunolabeling 
2.10.1. Table 2.8 Antibodies for flow cytometry 
 
 
2.10.2. Table 2.9 Primary & secondary antibodies for immunofluorescence 
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2.10.3. Table 2.10 Dyes 
 
 
 
2.10.4. Table 2.11 Software 
 
 
 
3. Methodology 
3.1. Cell culture 
3.1.1. Patient-derived cells and culture 
Human primary and recurrent GBMs were cultured in T75 or T150 flasks under neurosphere conditions at 
37°C in a humidified atmosphere of 5% CO2 in NPC culture medium. Cells were passaged 3 times per week 
every 2 days using a seeding density of 0,3-0,5x 106 cells/10ml [Campos B. et al. (2010)]. Human GBMs 
labeled as “Line#...” were also cultured under neurosphere conditions but in NSC medium [Galli R. et al. 
(2004)] and [Binda E. et al. (2012)].   
3.1.2. Mouse primary cells 
3.1.2.1. Subventricular zone NPC isolation  
Subventricular zone NPCs were isolated as previousy described [Talaverón R. et al. (2015)]. In brief, the 
mouse was sacrificed using cervical dislocation, and its body thoroughly sprayed with bacillol to prevent 
bacterial contamination. All dissection materials were previously washed and autoclaved. The neck was 
18 
 
sharply cut, and the brain excised and immediately placed in a 15ml tube filled with 1x sterile PBS. Under 
a microscope the subventricular zone was collected and placed in a 15ml tube filled with 3ml of DMEM-
F12 medium. When multiple brains were being processed, all samples were placed on ice as they were 
collected. To generate original mouse NPC cultures, pieces of SVZ were incubated in 3ml of trypsin for 15 
min at 37°C, homogenized with a sterile glass pipette, and further incubated 10 min at 37°C with 55,6µl of 
collagenase. Cell suspension was washed once with DMEM-10% FCS and twice NPC culture medium. The 
cells were then plated in a 6 well-plate by dividing the cells into 2 wells of 2ml each. The cells were 
subsequently checked every other day and 200µl of NPC culture medium was added until spheroid 
formation (approximately 5 days). Once spheroid formation was noticed and the center of the spheroids 
started to darken, they were gently disrupted, and the culture was up-scaled in 10-cm dish for expansion 
[Campos B. et al. (2010)] and [Ferrari D. et al. (2010)]. 
3.1.2.2. Generation of mouse GBM models 
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Figure 3.1 Generation of mouse glioma models from isolated pre-malignant SVZ NPCs. To generate 
mouse models of human glioblastoma, we used mice bearing a selection of genetic alterations of key tumor 
suppressors described in different human GBMs subtypes (p53, cdkn2a, PTEN, NF1) alone or in 
combination. After isolation and culture of SVZ NPCs, glioma models were obtained by inducing 
overexpression of proto-oncogenes (EGFR, EGFRvIII, PDGFB). Engineered cells were put back in culture 
for expansion. The first table summarizes how the different mouse glioma models were obtained showing 
the original NPC culture, the recombinant vectors (plasmid for transfection or lentivirus for transduction), 
and the name of the mouse glioma model. The second table indicates the different mouse gliomas organized 
by genetic subtypes. 
3.1.2.3. In vitro proliferation capacity and generation of NPC conditioned medium 
Mouse glioma models were evaluated for their in vitro proliferation capacity under basal cell culture 
conditions using microscopic evaluation and the MTS assay. To generate NPC conditioned medium, 0,5x106 
Wild type NPC / ml were cultured under neurosphere conditions in DMEM F-12. The conditioned medium 
was collected after 48h by centrifugation (800g, 30 minutes) and filtration though a 0,45μm pore membrane 
[Ma et al. (2011)]. The collected medium was then aliquoted, stored at -80°C and thawed on the day of 
experimentation. 
3.1.2.4. In vivo tumorigenicity 
All animal experiments were conducted following animal welfare regulations of the Bavarian government, 
Munich, Germany. To evaluate the capacity of the generated mouse gliomas to induce tumors in vivo, mice 
were anesthetized and immobilized in flat-skull position in a stereotactic head holder. 0,1x 106 cells/1 
µl/mouse were inoculated using a 30-gauge Hamilton syringe approximately 1,5mm posterior and 1,5 mm 
lateral to the bregma [Glass R. et al. (2005)]. After operation, the skin was sutured, and mice placed back in 
their cage for recovery. The animals were inspected twice a day until humane end-point. They were then 
anesthetized, perfused with PFA and their brain collected. Brains were placed in 30% sucrose for 
dehydration, then cryopreserved in tissueTek O.C.T solution. Tumorigenesis was evaluated by hematoxylin-
eosin staining and/or FET-PET imaging. 
3.1.2.5. Fluorescence immunocytochemistry 
Permeabilized cells were washed 3 times in 1x PBS. The primary antibodies incubated overnight at 4°C. 
The cells were washed 3 times with 1x PBS and incubated in the dark for 2 hours at room temperature with 
a mixture of fluorescently labeled secondary antibody and Hoechst 33342 for nuclear counter staining. 
Secondary antibody control staining was also carried out to exclude unspecific fluorescent staining. All 
wells were washed 3 times 5 min with 1x PBS. The chambers were dislocated from the wells and the excess 
PBS removed. One drop of fluorescence mounting medium was added on each well, the slide covered with 
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a coverslip and sealed with clear nail polish. Mounted slides were stored at 4°C in an opaque box until image 
acquisition. 
 
3.2. Routine molecular biology 
3.2.1. Protein extraction 
3.2.1.1. Total protein and nuclear protein 
5x106 cells were washed once with 1x PBS, and pelleted at 2500g, 5min at 4°C. Pellets were resuspended 
and vortexed in 500µl of RIPA buffer mix (480µl RIPA buffer, 5µl Phosphatase inhibitor cocktail 1, 5µl 
Phosphatase inhibitor cocktail 3, 10µl Protease inhibitor cocktail). The mixture was incubated on ice for 10 
minutes at 4°C, then vortexed and centrifuged 14000g, 20 min, 4°C. The protein supernatant was transferred 
to a new 1,5ml tube and stored at -80°C until use. For the study of transcription factors, the Signosis nuclear 
extraction kit was used. Nuclear proteins were extracted from at least 107 cells in two rounds of incubation 
in lysis buffer (1ml 1x Buffer I/BufferII, 10µl di-thio-threitol solution, 10µl protease inhibitor) at 4°C.  
3.2.2. Protein quantification 
Protein concentration was evaluated using the Bradford assay following manufacturer’s instructions. In 
brief, 1 µl of protein extract was mixed with 100 µl of assay buffer in triplicates. In parallel 1 µl of protein 
standards of known concentration (ranging from 0 to 2000µg/ml) were mixed with 100 µl assay buffer. The 
plate was incubated at 37°C for 10 minutes. Absorbance was recorded in a Versa Max microplate reader 
using the SoftMax Pro software. Blank was subtracted from all wells and protein concentrations were 
calculated by interpolating the sample protein values set as unknowns from the known protein concentration 
of the standard curve using the GraphPad Prism software.  
3.2.3. NMR profiling 
To identify metabolic alterations induced in CBD-sensitive GBMs upon treatment, 40x106 cells per 
condition were cultured in T150 flasks with 0,01% DMSO or 10μM CBD for 20 hours. The cell pellets were 
collected in 1,5ml tubes, flash frozen in liquid nitrogen, and stored at -80°C. Methanol-chloroform protocol 
[Lindon et al. (2005)] was used to isolate the polar extracts, and the water/methanol top phase containing 
the polar extracts was transferred to glass vials to remove the methanol using a stream of dry nitrogen. To 
evaluate differences between DMSO and CBD treated samples, a multivariate statistical data analysis using 
PCA and PLS-DA projection methods. 
 
3.3. Microbiology 
3.3.1. Chemo-transformation of bacteria for plasmid amplification 
50µl of chemo-competent E. coli were slowly thawed and incubated 30 minutes with 10µl (1µg) of plasmid 
on ice. The temperature was rapidly raised to 42°C for 45sec and the mixture quickly transferred on ice for 
2 minutes. Each tube received 500 µl of LB medium without antibiotics and taped in a 37°C shaking 
incubator for 60 minutes. Distant drops (10µl) of bacteria were seeded in LB-agar plates with the appropriate 
antibiotics and spread using an ethanol sterilized glass rod. Dishes were then closed, inverted, and placed in 
a 37°C dry incubator for 16- 24 hours. 
3.3.2. Plasmid amplification and glycerol stocks, and DNA purification 
To generate suspension bacterial cultures, three to six single colonies were picked per plate using the tip of 
a 200µl pipette and inoculated in 3ml LB medium supplemented with the appropriate antibiotics. The tubes 
were placed in a 37°C shaking incubator for 16- 24 hours. When a maxiprep was needed, 1,5-3 ml of 
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bacterial culture was inoculated in 250ml LB medium with the appropriate antibiotics.                             
Bacterial glycerol stock was generated using 500µl of a single colony culture. The suspension was 
transferred to a cryotube containing 500µl of 50% glycerol, and immediately stored at -80°C. Plasmids were 
amplified from glycerol stocks by scraping the icy glycerol stock with a 200µl pipette tip and inoculating it 
in 3ml LB medium with the appropriate antibiotics. 
3.3.3. Plasmid DNA purification and quantification 
Transfection grade plasmids were purified using Quiagen Plasmid Mini or Maxi kits with Quiagen-tip 20 
or Quiagen-tip 500 respectively. Manufacturer´s protocol was followed without any modification.                                         
To quantify the purified plasmid DNA, a biophotometer was used. Background was set with a water 
containing cuvette. 2µl of purified DNA was mixed with 98µl of DNAse/RNAse-free water and absorbance 
at 260/280nm was recorded. 
3.4. Plasmid transfection into mammalian cells 
106 cells/well in serum-free/antibiotic-free medium was seeded in a 6 well-plate and placed back in the 
incubator awaiting transfection. 3µg of plasmid was mixed and incubated 15 minutes at RT with 150µl of 
Optimem medium and 3µl of Plus-reagent. Then, 159µl of lipofectamine dilution (150µl Optimem + 9µl 
lipofectamine 2000) was transferred to each plasmid containing tube, incubated 30 min. at RT, before being 
added drop-wise to the plated cells. The day after transfection, the cells were collected from the wells, 
centrifuged, and plated in complete culture medium. 
3.5. Pantropic virus production and transduction 
PDGFB-GFP and PDGFB-DsRed viruses were a gift from Magdalena Goetz [Calzolari F. et al. (2008)]. 
Otherwise, lentiviruses were generated using the MISSION® third generation lentiviral packaging system 
in a BSL-2 setting, following manufacturer’s recommendations with minor changes. One day before 
packaging, HEK293T were plated in T75 flasks. The next day, they were co-transfected with packaging mix 
and transfer vector containing the gene of interest. 24 hours later, the cells were re-fed with fresh medium. 
Lentiviral particles were harvested on day 2 and 3 post-transfection, filtered, aliquoted and stored at -80°C 
until use. Pantropic viral transductions were carried out under BSL-2 conditions. On the day of transduction, 
0,2x106 cells in 5µl culture medium were transduced with 1,6µl of purified virus (500 µl of raw viral 
supernatant for unpurified virus). The mixture was incubated 37°C incubator for 1 hour, then received 500µl 
of culture medium. At 24-, 48-, and 72 hours the culture medium was changed and replaced with virus-free 
compete medium. After the last medium change, fluorescence expression of transduced recombinant viruses 
was checked using a fluorescence microscope. 
3.6. Flow cytometry 
3.6.1. Surface antigen staining for flow cytometry  
106 cells were cultured for the desired amount of time with or without treatment. The day of acquisition, the 
cells were collected, centrifuged, and washed once with 1xPBS. In 1,5 ml tubes, the cells were stained with 
fluorescently labeled surface antibody in FACS buffer (1µg/106cells/100µl) for 30 minutes on ice in the 
dark. Afterwards, the cells were washed twice with FACS buffer, and transferred to 1ml FACS tubes for 
acquisition in a BD LSR Fortessa.  
3.6.2. Intracellular staining and quantitative flow cytometry  
Cells were fixed with 100µl of IC fixation buffer for 20 minutes at RT. Without washing, 500µl of 1x 
Permeabilization buffer was added to each tube and centrifuged at 400g, 2 minutes at 4°C. The supernatant 
was discarded, and pellet resuspended and incubated in 500µl 1x permeabilization for 5 minutes. 
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Centrifuged pellets were resuspended in 50µl of 1x permeabilization buffer and 50µl of intracellular staining 
cocktail (1µg of each antibody) in FACS buffer. After 30 min. of incubation on ice in the dark, 500µl of 1x 
permeabilization buffer was added to each tube before centrifugation. The supernatant was discarded, and 
pellets washed twice with 500µl 1x permeabilization buffer. The cells were resuspended in 500µl FACS 
buffer and transferred to 1ml FACS tubes. The cells were kept on ice in the dark until flow cytometric 
acquisition.                                                                                                                    
To quantify the relative amount of fluorescence molecules that corresponds to the acquired median 
fluorescence intensity (MFI), rainbow calibration particles (RCP) where acquired the same day and using 
the same laser settings as the samples.  Exported fcs files were analyzed in FCS express5 for their MFI and 
their MEFL calculated using the standard curve of known RCP MEFL concentrations. The normalized 
median fluorescence intensity (nMFI) was also calculated by dividing the MFI by the number of events 
(MFI/number of events). 
3.7. Automated plate assays 
3.7.1. In vitro cytotoxicity assay 
Cytotoxicity was detected using the CytoTox-Fluor™ cytotoxicity assay from Promega. In 96 well-plates, 
3 x103 in 50µl (5 replicates per condition) were treated for 24 hours with 50µl of vehicle/drug in NPC 
medium without phenol red. 40µl of cells and diluted bis-AAF-R110 substrate (1:1 ratio) incubated for 2 
hours before measuring fluorescence intensity in the Tecan InfiniteF200 fluorescence plate reader 
(485nmEx/520nmEm). Blank was substracted from all wells and the fluorescence read-out for untreated 
cells (vehicle control) was normalized to 1. Read-outs from treated cells were normalized to those of 
untreated cells and fold change of relative cytotoxicity calculated for each well. Outliers were detected and 
omitted, if any, using the Grubbs test. Graphs were generated using the GraphPad Prism software version 
5.01. 
3.7.2. In vitro viability assay (MTT) 
The CellTiter 96® Non-radioactive Cell Proliferation Assay was used according to manufacturer´s 
instructions. Cells were seeded and treated as in the cytotoxicity assay. After 72 hours of incubation at 37°C 
in a humidified atmosphere, each well incubated with 15µl of dye solution for 4 h at 37°C. During this 
incubation period, living cells with active metabolism convert the MTT tetrazolium component of the dye 
solution into a formazan product. To solubilize the formazan product, 100µl of solubilization/stop solution 
was added to each well and incubated 1 hour at 37°C. The absorbance was then recorded using an 
absorbance plate reader set at 570nm using the SoftmaxPro software. Blank was subtracted from all wells 
and fold change to vehicle control was calculated. 
3.7.3. In vitro viability assay (MTS)  
The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay was used according to 
manufacturer´s instructions. Cells were seeded and treated as in the MTT assay. After 72 hours of incubation 
at 37°C in a humidified atmosphere, each well incubated with 20µl of MTS/PMS solution for 4 h at 37°C. 
To stop the reaction, 25µl of 10% SDS solution was added to each well and incubated 1 hour at 37°C. The 
absorbance was then recorded using an absorbance plate reader set at 490nm using the SoftmaxPro software. 
Blank was substracted from all wells and fold change to vehicle control was calculated. 
3.7.4. Activated ER stress transcription factor array 
The Signosis ER stress activation profiling plate array was used to simultaneously detect alterations in 16 
ER related transcription factors: XBP-1, ATF4, ATF6, GADD153/CHOP, CBF/NFY, SREBP1, YY1, ERR, 
ATF3, AP-1, FOXO1, IRF, p53, NFkB, NRF2/ARE, HNF4 [Jiang S. et al. (2016)]. Samples were treated 
with DMSO or CBD for 20h. Nuclear proteins were extracted using the Signosis kit SK0001 and quantified 
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using the Bradford assay. For each sample, 10μg of nuclear extract were mixed with probe mix and 
transcription factor bound probes were retained on a separation column. After removing free probes, bound 
probes were eluted, denatured and hybridized to the pre-coated array plate overnight at 42◦C. Biotinylated 
probes were detected with streptavidin-HRP using the luminescence filters of a TECAN plate reader.  
3.7.5. ARE-luciferase promoter reporter assay 
GBM cells were co-transfected with 4.74-hRluc and 4.27-luc2P (minimal promoter) or 3.37-luc2P(ARE). 
[Schagat T. et al. (2007)]. After weeks of hygromycin selection, 0.1 x 106 cells were treated with DMSO or 
CBD for 24 hours.  96 well plates were removed from incubator and each well received 75μl of Dual-glo 
luciferase assay reagent, and firefly luciferase activity measured 10 minutes later in TECAN reader. 75μl of 
Dual-glo stop & glo was added and renilla luminescence measured. The ratio of ARE reporter luminescence 
to control reporter was calculated and compared in DMSO / CBD treated wells. 
 
3.8. ProteoTuner, NFkB promoter fluorescence reporter assay 
Patient-derived Glioblastoma cells were transfected using lipofectamine as previously described. Stable 
transfectants were used in four experimental conditions: Shield alone (detection of GBM cells basal 
promoter activity), Shield+CBD, and Shield + TNFα (positive control for NFkB promoter activity). Green 
fluorescence of treated cells (active NFkB promoter) was examined by fluorescent microscopy or flow 
cytometry. 
 
3.9. In vivo experiments: tumor implantation, in vivo therapy, and tissue processing 
Athymic nude mice were anesthetized and inoculated with 0.1 x 106 cells in the right hemisphere. The 
wound was cauterized, and mice placed back in their cages for awakening before being brought back to 
animal housing. The mice were followed and inspected twice a day in the morning and late afternoon.                          
For in vivo therapy, treatment was prepared daily by mixing vehicle (0) or CBD (15mg/kg) EtOH aliquots 
(-20◦C) to room temperature vehicle solution. Mice were transported to operation room, weighed, and 
received 10 μl/g of freshly mixed vehicle or CBD i.p.                                    
At humane end-point, the animals were anesthetized and perfused with 4% PFA via cardiac puncture. Brains 
were collected in 4% PFA, transferred in sucrose for 3 days and embedded in cryomatrix. Liquid nitrogen 
frozen brains were sliced in dry ice and floating sections stored at -20◦C until use. 
3.10. Ex vivo experiments 
3.10.1. Tumor biopsy dissection and processing 
Athymic nude mice bearing patient-derived GBM xenografts were sacrificed and brains collected. The 
tumor was dissected, tumor biopsy cut into 10mg pieces, and mashed through cell strainer. One part of cell 
suspension was stained with human HLA A, B, C-AlexaFluor647 and 20μM H2DCFDA in 1x PBS for 30 
minutes at 37◦C. The rest was stained with H2-DCFDA for glass capillary detection in the IOS [Gorpas D. 
et al. (2017)] and [van Dam G. M. et al. (2011)]. 
3.10.2. Ex vivo labeling of live tumor biopsies 
For ex vivo imaging of GBM ROS levels, suspensions of filtered mashed brains (0.5x106 cells) were either 
unstained or stained with Hoechst 33342 (1:1000 dilution), 30μM H2DCFDA (intracellular ROS) or 
Hoechst 33342 and H2DCFDA. After 30 minutes at 37◦C, the dyes were washed away, and tumor soup 
loaded in glass capillaries for imaging. 
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4. Results 
4.1. Human and mouse GBMs and their characterization 
4.1.1. Characterization of human GBMs 
4.1.1.1. Patient derived human GBMs proliferate in vitro under stem cell conditions 
Patient derived GBMs were cultured under spheroid conditions in their respective culture media. Three 
times per week, the spheroids were passaged by gentle disaggregation, splitting, and re-plating in fresh 
culture medium. Figure 4.1 illustrates a microscopic evaluation of the cultured spheroids before passaging 
and shows the variety of growth pattern observed for different GBMs. 
 
Figure 4.1 Microscopic visualization of patient derived GBM spheroid cultures. GBM cells were cultured under 
spheroid conditions and the cultures were monitored using a light microscope at 20x magnification. The name of cells 
used is on the left-hand corner of each picture and the black scale bar indicates 100μm. 
 
4.1.1.2. Patient derived GBMs retain the capacity to induce glioblastoma in vivo 
After successful culture in vitro, we evaluated the ability of a selection of GBM cells to induce tumors in 
athymic nude mice brains. 
We found that different GBM cells have different time-course of tumorigenicity and that the generated 
tumors are not alike. Some tumors are very solid and compact with well-defined borders (Line#2, NCH644, 
GBM14), whereas others present a gel-like appearance and are difficult to demarkate (NCH421k) [Figure 
4.2]. 
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Figure 4.2 In vivo tumorigenicity of patient derived glioblastoma after implantation in athymic nude mouse 
brain. Picture of dissected mouse brain showing the tumor in the right hemisphere (A) and MRI scans for GBM14 
and Line#2 (B). 
 
4.1.2. Generation of mouse models of GBMs 
NPCs bearing floxed or knock-out genes (TRP53 wt/mutant, NF1, PTEN, or cdkn2a), alone or in 
combination, were isolated from mouse subventricular zone, cultured under neurosphere conditions, and 
transduced with lentiviral vector expressing CRE recombinase. These pre-malignant cells were further 
virally transduced or transfected to overexpress PDGFB or EGFR/EGFRvIII in order to obtain fully 
malignant glioma cells. Spheroids of mouse gliomas are illustrated in Figure 4.3. 
 
 
Figure 4.3 Spheroids of generated mouse gliomas. Microscopic evaluation of transduction efficiency for the 
generation of mouse gliomas. Fluorescence imaging for transduction efficiency at 40x magnification after viral 
transduction of SVZ-NPCs. Mouse cells were floxed or knock-out for cdkn2a, p53, PTEN, NF1 and transduced with 
viral particles CRE, PDGFB, or EGFRvIII concomitantly with a fluorescence tag (GFP). The scale bar is at the lower-
right-hand corner of each picture and indicates100μm. 
 
4.1.3. Characterization of mouse glioma models 
4.1.3.1. Glioma mouse models differentially proliferate in vitro under stem cell conditions 
Visual inspection of the cells during culture suggested that they had different proliferation rates. Indeed, 
we found that at comparable seeding density, mouse glioma cells tend to form bigger spheres and grow 
faster than NPC-wt. [Figure 4.4].  
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Figure 4.4 Visual inspection of in vitro cultures of mouse glioma models. Cells were seeded at a density of 0,2 x 
106 in 10 ml of culture medium. Pictures were acquired 2 days after seeding using a light microscope at 20x 
magnification. Scale bars are in black and indicate 100μm.  
 
4.1.3.2. Generated mouse gliomas are distinct in their proliferation capacity 
 
 
Figure 4.5 End-point (72h) evaluation of in vitro proliferation capacity of mouse gliomas. The cells were seeded 
at a density of 3000 cells/well in 100μl of phenol red-free culture medium. At 72 hours, the MTS assay was carried 
out. Background was subtracted from all wells. The graph indicates the fold change of the mean +/- SEM of the 
absorbance of gliomas mimicking different GBM subtypes (colored bars) compared to NPCwt (gray bar).Statistical 
significance was evaluated using two-tailed paired t test. 
 
To confirm that differences in proliferation capacity/metabolic activity exists between different gliomas and 
non-malignant NPCs, we performed an MTS assay at 72 h end-point starting with a seeding density of 3000 
cells/wells (in quintuplicates) for all gliomas. We found that compared to wt-NPCs, mouse gliomas with 
genetic alterations characteristics of different human GBM subtypes, had different metabolic activities 
[Figure 4.5]. 
 
4.1.3.3. In vivo tumorigenicity of mouse glioma models depends on their genetic background 
 
To verify the capacity of engineered mouse gliomas to generate tumors in vivo, immunocompetent mice 
were inoculated with cultured mouse glioma cells in the right hemisphere. At humane end-point, the mice 
were processed and the tumorigenicity of the inoculated cells evaluated after H&E staining. We found that 
tumorigenicity and humane-end was achieved rapidly with two mouse glioma models: p53KO-PDGFB 
(proneural) needed about 57 days and cdkn2aKO-EGFRvIII (classical) about 15 days [Figure 4.6]. 
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The brain slices of the two mouse models were also imaged for the fluorescence of inoculated mouse glioma 
cells. As the viral vectors used in engineering the glioma cells also expressed a GFP marker, the brain slices 
were only counterstained with Hoechst 33342 (blue) and the tissue directly imaged in a fluorescence 
microscope.  
 
Figure 4.7 Fluorescence imaging of mouse brains inoculated with genetically engineered glioma cells. 
Immunocompetent mice were inoculated with 10 000 mouse glioma cells in the right hemisphere. 40μm brain slices 
were counterstained with Hoechst 33342 and mounted for fluorescence imaging. Mouse glioma models cdkn2aKO-
EGFRvIII-GFP (top) and p53KO-PDGFB-GFP (bottom) showing from left to right:  Hoechst staining for nuclei 
showing accumulation in the right hemisphere; GFP-positive tumor cells; overlay of GFP-glioma cells and nuclear 
Hoechst staining. Images were acquired at 10x magnification, scale bar = 100μm. 
 
We found that the GFP signal allowed a good localization of the tumors in situ. The Hoechst counterstaining 
indicates a massive accumulation of cell nuclei in the same territory of the GFP-positive tumors [Figure 
4.7]. 
 
 
Figure 4.6 H&E staining of mouse glioma models. 
Immunocompetent mice were inoculated intracranially 
with 10 000 cells of engineered mouse gliomas 
representative of two GBM subtypes: cdkn2aKO-
EGFRvIII-GFP at 15 days post inoculation (left) or 
p53KO-PDGFB-GFP at 57 days post inoculation (right). 
40μm brain slices were stained with Hematoxylin-Eosin  
and tumors were visualized in a light microscope at 5x magnification. The scale bars indicate 20μm. 
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4.2. Endovanilloid-rich NPCwt conditioned medium induces cytotoxicity in subsets 
of mouse GBMs 
It was previously published that in the young mouse brain, NPCwt could migrate to and encircle gliomas. 
There, they were shown to secrete different lipids called endovanilloids. These endovanilloids by activation 
of TRPV1 receptors activated ER stress and induced cell death in the gliomas [Stock k. et al. (2012)]. We 
then investigated the anti-tumorigenic role of NPC-wt conditioned medium on generated mouse gliomas. 
Mouse glioma cultures representative of glioblastoma subtypes (classical, proneural, mesenchymal) have 
been tested.  In this screen, NPCwt conditioned medium shown to be toxic to a selection of mouse gliomas 
[Figure 4.8]. 
 
Figure 4.8 NPCwt conditioned medium (CM) induces cytotoxicity in subsets of mouse gliomas. Mouse glioma 
cells were incubated with unconditioned medium or NPCwt CM for 24 hours and in vitro cytotoxicity detected. The 
graph illustrates the mean +/- SEM of the fold change of cytotoxicity. Two-tailed paired t test statistical analysis was 
used to compare unconditioned medium (grey bar) to cells cultured in conditioned medium (colored bar).  
 
These results confirm that endovanilloids secreted by NPCwt is not toxic to healthy NPCs while they are 
capable to kill some gliomas. We also show that some mouse gliomas can resist the cytotoxicity effect of 
endovanilloids.  
 
4.3. Plant derived vanilloid cannabidiol induces cytotoxicity in mouse and human 
GBMs with different genetic signatures  
To verify if the endovanilloids effect could be obtained with clinical-grade vanilloids, we evaluated the 
effect of plant-derived vanilloid Cannabidiol (CBD) on engineered mouse gliomas and patient derived 
GBMs.  
4.3.1. In vitro, CBD is toxic to a selection of mouse of human GBMs 
To evaluate the cytotoxicity of CBD in vitro, mouse gliomas were subjected to the cytotoxicity assay as 
performed for the effect of NPCwt CM. We set a threshold of cytotoxicity to 2-fold of the effect of the 
vehicle treated cells to exclude inter-experiment variability. 
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Figure 4.9 CBD is toxic to subsets of mouse GBM models. Mouse cells were treated with 0,01% DMSO (vehicle 
control) or 10µM CBD (drug). The cytotoxicity detection was carried out as previously. The graph shows the fold 
change of CBD cytotoxicity compared to vehicle control for each mouse glioma. The experiments were repeated at 
least 3 times. Statistical analysis: two-tailed paired t test; mean & SEM.  
 
We found that CBD does not induce significant cytotoxicity in NPCwt as well as some mouse gliomas e.g. 
the mesenchymal mouse glioma p53flx-NF1flx-CRE. However, we show that CBD induces significant 
cytotoxicity in most mouse gliomas and is more than 5-fold more toxic compared to vehicle control in some 
proneural gliomas with mutant p53 (R172h, R175H, R273H, V143A) [Figure 4.9]. 
4.3.1.1. CBD is toxic to mouse gliomas but not NPCwt 
In parallel with the cytotoxicity assay, we also corroborated our findings by microscopic evaluation of the 
treated cultures [Figure 4.10].  
 
 
Figure 4.10 Visual inspection of mouse gliomas upon CBD treatment. Mouse NPCwt and glioma cells used for 
the CBD cytotoxicity assay. NPCwt cells were treated with DMSO (A) or CBD (A’); and mouse gliomas cdkn2aKO-
EGFRvIII DMSO (B), CBD (B’); p53R172H-PDGFB DMSO (C), CBD (C’). Microscopic images captured at 20x 
magnification just before the cytotoxicity detection using a light microscope. Scale bars = 200µm. 
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Wild-type NPCs that were not affected by CBD in the cytotoxicity assay also did not seem to be affected 
when the cultures were observed under a microscope. The same is true for the gliomas that showed to be 
sensitive to CBD in the cytotoxicity assay such as cdkn2aKO-EGFRvIII and p53R172H-PDGFB [Figure 
4.10]. 
 
4.3.1.2. CBD decreases spheroid size of mouse models of human GBMs 
The effect of CBD on glioma spheroids was also evaluated in parallel to the cytotoxicity assay, and we 
quantified changes in spheroid size 48- and 72-hours post treatment.  
 
 
   
Figure 4.11 CBD treatment decreases mouse glioma spheroid size. Mouse NPCwt and 2 mouse gliomas shown to 
be very sensitive to CBD, p53R172H-PDGFB (proneural) and cdkn2aKO-EGFRvIII (classical), were treated with 
0,01% DMSO or 10µM CBD. At 48- and 72- hours post treatment the wells were microscopically inspected, and 
pictures of spheroids acquired. The diameter of spheroids was measured using FiJi (A), and the fold change of CBD 
treated spheroid size compared to vehicle treated spheroids was calculated (B). Graphs with mean & SEM were 
generated and statistical significance evaluated with two-tailed paired t test comparing DMSO to CBD treated at 48- 
and 72 hours for each group. 
 
Validating our cytotoxicity assay results, we found that CBD does not affect the size of NPCwt, while 
significant changes are observed for the proneural p53R172H-PDGFB and the classical glioma cdkn2aKO-
EGFRvIII. For the mouse gliomas, the DMSO treated spheroids grew in diameter over time, but the CBD 
treated spheroids were disaggregated [Figure 4.11]. 
 
 
4.3.2. CBD induces cytotoxicity in human GBMs to different extent 
 
31 
 
The cytotoxicity effect of CBD on patient-derived GBMs was evaluated in the CytoToxFluor cytotoxicity 
assay, as performed for the mouse gliomas [Figure 4.9]. 
 
 
Figure 4.12 In vitro, CBD induces cytotoxicity in human GBMs to different extent. Human GBMs were 
investigated in the cytotoxicity assay using the same settings for the mouse gliomas [Figure 4.9]. The generated graph 
indicates the fold change of cytotoxicity in GBM cells treated with 0,01% DMSO (left bar) or 10μM CBD (right bar) 
compared to the vehicle control (DMSO). The different human GBMs were grouped on the graph by genetic subtype 
using a color-code: proneural GBMs in shades of blue, classical GBMs in shades of green, mesenchymal GBMs in 
shades of pink, and unclassified GBMs in shades of orange. Mean +/- SEM; two-tailed paired t-test (n = 3 - 10) 
 
As obtained for the mouse gliomas, we found that CBD exerts cytotoxicity effects on human GBMs to 
different extent [Figure 4.12]. We categorized human GBMs based on CBD response spectrum from the 
cytotoxicity screening as good responders when the cytotoxicity induced is more than 2-fold compared to 
vehicle treated, and as low-CBD responders when it is below 2-fold. 
 
As for the mouse glioma cytotoxicity, we visually inspected the treated cells used in the assay to verify if 
the quantified cytotoxicity was related to some changes in the cultures. 
 
Figure 4.13 Visual inspection of cells used in the in vitro cytotoxicity assay of CBD in human GBM spheroids. 
Human GBM cells were plated for the cytotoxicity assay as previously described for the mouse cytotoxicity screening 
[Figure 4.9]. Before starting the detection of cytotoxicity, the treated wells were inspected with a light microscope 
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and pictures acquired at 20x magnification. DMSO treated cells for each GBM are shown left and the CBD treated 
are on the right. Scale bars = 100μm. 
 
We again observed that CBD treated wells show spheroids which seem smaller with a more disaggregated 
appearance. In cases where the GBMs grow as adherent, treating with CBD caused loss of adherence e.g. 
Line#11 [Figure 4.13]. 
 
4.3.3. Long-term follow-up post CBD treatment indicates that induced cytotoxicity is durable 
To verify the durability of CBD effect, the cells treated and used in the cytotoxicity assay were kept in 
culture for 11 days.  At day 4 and 11 the cells were imaged, and viable cells counted using trypan blue 
exclusion. 
 
 
Figure 4.14 CBD induced cytotoxicity is durable. Two good-CBD responders were used for this assay: GBM 
Line#2 and GBM29. Cells were plated as previously described for cytotoxicity screening [Figure 4.9].  At day 4 and 
11, plated cells were visually inspected using light microscopy. The 5 wells were pooled and the viable cell count of 
untreated and CBD treated wells was evaluated using trypan blue exclusion. Graph show the viable cell count obtained 
for untreated wells (left bars) and CBD treated wells (right bars). Counts at day 4 post treatment are indicated in light 
blue and at 11 days are in darker blue. Microscopic inspections at day 11 post treatment are indicated under the graphs 
and show for both lines untreated samples (left) and CBD treated samples (right) at 10x magnification. The scale bar 
indicates 100μm. 
 
We found that while cells in untreated wells continued to grow from day 4 to 11, cells in CBD treated 
wells kept dying until viable cells were undetectable at day 11 [Figure 4.14]. 
4.3.4. Six-hour-pulse CBD treatment corroborate the findings of the CBD cytotoxicity on human 
GBMs 
In clinical trials involving healthy volunteers per-os, CBD was shown to have peak activity from 55 minutes 
to 3 hours after administration [Blessing E. M. et al (2015)]. To study the effect of CBD within the range of 
its pharmacokinetics and bioavailability in the brain in our in vitro setting, we performed a 6h-pulse CBD 
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treatment. We pulse treated our collection of human GBMs for 6 hours, removed the drug-containing 
medium and replaced it with regular culture medium. Then the GBM cells viability was evaluated by 
counting viable cells using trypan blue exclusion at 24-, 48-, 72 hours post pulse treatment.  
 
Figure 4.15 Evaluation of viable GBM cells after 6-hour-pulse CBD treatment. GBM cells were plated in 6 well-
dishes at a density of 106 cells/well in NPC culture medium. Wells were treated either with 0,01% DMSO or 10μM 
CBD. After 6 hours of incubation, the treatments were removed from all wells and the cells plated in drug-free NPC 
culture medium. Viable cells were counted at 24-, 48-, and 72 hours using the trypan blue exclusion method. The 
graphs indicate the percentage of viable cells over a 3-day-period.  
 
Doing so, we confirmed the cytotoxicity assay findings where the GBMs identified as good-CBD responders 
were the only ones dying after 24 and 48 hours. Interestingly, at 72 hours massive death is observed for the 
known CBD responders whereas in low-responders viable cell counts were either unchanged or higher in 
CBD treated when compared to the vehicle controls [Figure 4.15].  
 
4.4. The p53 status of human GBMs determines the cell death mode induced by CBD 
4.4.1. CBD induces caspase dependent death in p53wt GBMs 
To clarify the mode of cell death induced by CBD, we screened the effect of the pan-caspase inhibitor Q-
VD-OPh (quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone), on human GBMs in 
combination with CBD. Q-VD-OPh is a broad-spectrum caspase inhibitor that is effective at low doses (5 
μM) and which has been shown to inhibit apoptotic pathways where caspase 8/10, caspase 9/3, and caspase 
12 are implicated [Caserta T. M. et al. (2003)].  
 
34 
 
 
Figure 4.16 The p53 status of human GBMs determines the cell death mode induced by CBD. To determine if 
CBD kills human GBMs via apoptosis, the effect of pan-caspase inhibitor Q-VD-Oph on CBD induced cytotoxicity 
in selected GBMs was evaluated: p53mu GBMs (Line#2, NCH588J, NCH644), p53wt GBMs (Line#6, Line#11, 
GBM20). Four conditions were used in a set of cytotoxicity assays: 0,01% DMSO (20 hours), 10μM CBD (20 hours), 
10μM Q-VD-Oph (3 hours), 10μM Q-VD-Oph (3 hours) and 10μM CBD (20 hours). The cytotoxicity assay was 
conducted as previously described [Figure 4.9] and repeated in 3 to 5 independent experiments. Panel A indicates the 
mean +/- SEM of the fold change of cytotoxicity compared to vehicle control for all treatment conditions. One-way 
ANOVA with Bonferroni multiple comparison test was used to statistically compare the cytotoxicity of Q-VD-Oph 
or CBD alone to the dual effect of Q-VD-Oph and CBD. Panel B is a schematic summary of the cytotoxicity findings, 
showing that if a p53wt GBM is treated with CBD it dies in a caspase dependent manner, whereas a mutant p53-GBM 
dies in a caspase independent manner. 
 
Also, it was shown to be a more potent inhibitor than z-VAD-fmk (benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone) and Boc-D-fmk (Boc-aspartyl(OMe)-fluoromethylketone), which only inhibit some 
classes of apoptotic caspases [Yee S. B. et al (2006)]. Moreover, Q-VD-OPh does not show toxicity in vitro 
or in vivo even at prolonged treatment or high doses respectively up to 50μM and daily administration of 
10mg/kg for up to 4 months [Keoni C. L. et al. (2014)].  
To know if CBD kills GBM via apoptosis, patient-derived GBM cultures, known to be sensitive to CBD in 
the cytotoxicity screen, were pre-treated with Q-VD-OPh for 3 hours and then received either the vehicle 
control (DMSO), Q-VD-OPh, CBD, or a combination of Q-VD-OPh and CBD. After 20 hours of further 
incubation, the cytotoxicity assay revealed that Q-VD-OPh could only decrease CBD induced death in 
p53wt GBMs that are otherwise sensitive to CBD. This suggests that GBM cells that express a wild-type 
version of p53 would die in a caspase dependent manner when treated with CBD [Figure 4.16]. 
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Scientific findings have shown that tumor cells die in multiple modes of regulated cell death [Maltese W. 
A. et al (2014)]. As we could determine the death mode induced by CBD only for some of the investigated 
GBMs, we developed a cell death flow cytometry panel that includes a phenotypic live/dead labeling and 
markers for three major regulated cell death modes: apoptosis (increase in cleaved PARP1) [Soldani C. et 
al. (2002)], necroptosis (increase in MLKL/P-MLKL) [Yoon S. et al. (2017)] and autophagy (p62 
degradation) [Bjørkøy G. et al (2009)]. The flow cytometry approach allowed us to quantify at a single cell 
level, GBM cells that could be dying via multiple pathways. 
 
 
 
Figure 4.17 CBD induces apoptosis or autophagy in human glioblastoma. Human GBMs treated with DMSO or 
CBD were stained for makers of apoptosis (cleaved PARP1 increase), necroptosis (p-MLKL increase), and autophagy 
(p62 decrease) and fluorescence signal acquired by flow cytometry. Graphs indicate the mean +/- SEM of the 
percentage of marker positive cells for all 3 markers of apoptosis (Cleaved PARP1), necroptosis (p-MLKL), and 
autophagy (p62). The measurements were repeated in 3 to 6 independent experiments and the statistical significance 
of the findings was evaluated with two-tailed paired t-test comparing CBD treated to DMSO treated conditions. 
 
We found that, for the GBM tested, CBD does not induce death via necroptosis. But for the p53-mutant 
GBMs that were not dying in a caspase dependent manner in the previous assay [Figure 4.16], we found 
that CBD induced a significant decrease in p62, which suggests an autophagic cell death. A mixture of 
apoptosis and autophagy was found in a p53wt-GBM (GBM20) [Figure 4.17]. 
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4.5. CBD alters the metabolic profile of human and mouse GBMs 
Now that we uncovered the major cell death modes that are induced in GBMs upon CBD treatment, we 
investigated further the metabolic pathways that are mobilized in GBMs that are responsive to CBD. We 
made use of NMR to profile CBD induced metabolite alterations in polar fractions of mouse and human 
GBMs. First, a clear separation between DMSO and CBD treated cells could be observed showing a real 
“CBD effect” in human and mouse GBMs [Figure 4.18 A & B]. Then, the metabolites that are altered upon 
treatment were identified, along with the variations induced by CBD (increase or decrease compared to 
control) [Figure 4.18 A’ & B’].  
 
Figure 4.18 NMR profiling reveals metabolic alterations induced by CBD in human and mouse GBM. One 
human GBM NCH644 (A/A’) and one mouse GBM cdkn2aKO-EGFRvIII (B/B’), known to be very sensitive to CBD 
were selected for the assay. To evaluate differences between DMSO and CBD treated samples, a multivariate 
statistical data analysis using PCA and PLS-DA projection methods was carried out (A/B) and the metabolites altered 
upon CBD treatment in human NCH644 and mouse cdkn2aKO-EGFRvIII GBMs are shown in A’ and B’ respectively.  
 
Similar trends in the metabolic alterations have been found between human and mouse GBMs [Figure 4.18 
A’, B’] and include increase in acetate and glutamine, and decrease in alanine, ATP, myo-inositol, and 
phosphorylcholine.  
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4.6. In GBMs, CBD does not induce ferroptosis or lipid peroxidation 
It has been shown that glioblastoma death could be induced by inhibiting cholesterol uptake with the 
inhibitor LXR-623 [Villa G. R. et al. (2016)]. Lipids and lipid modifications seem then to play a crucial role 
in tuning glioblastoma survival and their manipulation might be used as a strategy to eradicate this disease.  
Indeed, lipid peroxidation derived ROS (lipid ROS) has been shown to be closely linked to iron metabolism 
in the newly described cell death mode ferroptosis [Dixon S. J. et al. (2012)] and [Toyokuni S. et al. (2017)]. 
To check the impact of lipid peroxidation in CBD induced glioma cell death, we used the lipid peroxidation 
inhibitory molecule Ferrostatin-1(Fer-1) [Dixon S. J. et al. (2012)] alone or in combination with CBD in the 
CytoTox-Fluor™ cytotoxicity assay. 
 
 
Figure 4.19 CBD and lipid peroxidation. GBM cells were screened in a cytotoxicity assay as previously described, 
testing for the effect of lipid peroxidation inhibitor Ferrostatin 1 on CBD induced GBM cytotoxicity. 4 conditions 
were used in a set of cytotoxicity assays: DMSO (20 hours), CBD (20 hours), Ferrostatin 1 (3 hours), Ferrostatin 1 (3 
hours) and CBD (20 hours). The cytotoxicity assay was conducted as previously described [Figure 4.12] and repeated 
in 2 to 5 independent experiments. The graph indicates the mean +/- SEM of the fold change of cytotoxicity compared 
to vehicle control for all treatment conditions. One-way ANOVA with Bonferroni multiple comparison test was used 
to statistically compare the cytotoxicity of CBD alone to the dual effect of Ferrostatin 1 and CBD. Statistical results 
for significance comparing to vehicle are in black, and to CBD are in red. 
 
Interestingly, CBD induced cytotoxicity could be significantly reduced by ferroptosis and lipid peroxidation 
inhibitor Fer-1 in most GBMs regardless of their subtype [Figure 4.19]. Apart from one proneural GBM, 
inhibiting ferroptosis with Fer-1 significantly reduced CBD cytotoxicity; with the most significant decrease 
observed in p53wt/ caspase dependent dying GBMs. These first results triggered our interest in a potential 
role of ferroptosis in CBD induced GBM death. Therefore, we investigated this pathway further. Ferroptosis, 
death by lipid peroxidation, is characterized by the down-regulation of system xC (SLC7A11), high iron 
levels and accumulation of lipid ROS [Dixon S. J. et al. (2012)]. As glioblastoma produce high levels of 
reactive oxygen species (ROS) [Moloney J. N. et al. (2017)], we also explored the importance of ROS in 
GBM cell death.  
Endoplasmic reticulum (ER), mitochondria and peroxisomes are the 3 main cellular organelles producing 
ROS. As these ROS can be further categorized in 2 types, lipid ROS (lipid hydroperoxides) and the non-
lipid ROS or water-soluble ROS e. g. hydrogen peroxide (H2O2) superoxide anion (O2−.), hydroxyl radical 
(•OH) [Birben E. et al. (2012)], we subsequently screened a selection of human GBMs by flow cytometry 
for these 2 ROS categories. It was recently published that glioblastoma cells heavily rely on cholesterol for 
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survival, and by blocking cholesterol uptake with the small molecule LXR-623, glioblastoma cell death 
could be induced both in vitro and in vivo and was associated with tumor shrinkage and prolonged survival 
in orthotopically implanted mice [Villa G. R. et al. (2016)]. Potential lipid peroxidation in patient derived 
GBMs was assessed using the ImageIt lipid peroxidation kit by flow cytometry. 
 
 
Figure 4.20 CBD does not induce lipid peroxidation in GBMs. GBM cells were treated either with DMSO or CBD 
for 72 hours, then stained with the ImageIt Lipid peroxidation kit for lipids (red fluorescence) and lipid 
hydroperoxides (green fluorescence). The graph represents the mean +/- SEM of the ratio of lipid hydroperoxides 
(LHP) and lipids (L). DMSO treated samples (gray bar) were compared to CBD treated cells (green bar) using two-
tailed paired t test. 
 
 
At 24 hours post-treatment, no changes were detected in neither low- nor good-CBD responders. At 48- and 
72 hours we could not detect any change in the ratio of lipids/lipid hydro-peroxides in low/non-CBD 
responders. However, alterations in lipid hydroperoxides/lipids ratios (increase or decrease) were observed 
in good CBD responders [Figure 4.20]. 
4.7. Evaluation of CBD induced ER stress in human GBMs 
One pathway previously associated with vanilloid induced glioma death is the ER stress pathway [Stock K. 
et al. (2012)]. To verify the capacity of CBD to induce ER stress in human GBMs, we performed an activated 
ER stress transcription factor array. This assay shows ER related transcription factors that are activated. 
When activated, the transcription factors can bind complementary DNA consensus sequences. In this assay, 
we compared responses in nuclear extracts of a low-CBD responder (NCH421k) to a good-CBD responder 
(Line#2).  
 
39 
 
 
Figure 4.21 CBD induces alterations in the activation of ER stress transcription factors. GBM cells were cultured 
in NPC culture medium supplemented with 0,01% DMSO or 10μM CBD for 20 hours. 10µg of nuclear proteins were 
used in the ER stress activated profiling plate array to detect simultaneously 16 ER related transcription factors: XBP-
1, ATF4, ATF6, GADD153/CHOP, CBF/NFY, SREBP1, YY1, ERR, ATF3, AP-1, FOXO1, IRF, p53, NFkB, 
NRF2/ARE, HNF4. Graphs indicate fold change of relative luminescence unit (RLU) of CBD treated samples (green 
bars) compared to DMSO control (gray bars) for NCH421k and Line#2. Based on the p53 null status of NCH421k, a 
threshold of relative luminescence unit (RLU) was set by removing all values detected as less than the RLU of p53 in 
NCH421k. Paired t test was used to evaluate differences between DMSO and CBD treatments but was not significant. 
 
In these two GBMs, we revealed differentially regulated transcription factors implicated in inflammatory 
response (IRF, NFkB), lipid metabolism (SREBP1, ERR, FOXO1), antioxidant response (NRF2/ARE) 
[Figure 4.21]. Although the results were not statistically significant, they will serve as a basis for further 
investigations clarifying the effects of CBD using other assays (fluorescence immunocytochemistry, flow 
cytometry and other reporter assays). 
 
4.8. CBD decreases the proportion of GBM membrane lipids  
Although no significant changes in lipid hydroperoxides were obtained upon CBD treatment we explored 
alterations in GBM lipids upon CBD. By fluorescence microscopy, we observed that CBD changed lipid 
distribution and staining [Figure 4.22 panel A].   
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Figure 4.22 CBD decreases GBM membrane lipids.  GBM cells (Line#2, NCH421k) were treated either with 0, 
01% DMSO or 10μM CBD for 20 hours, after which, the treatment was removed and replaced with 1x PBS containing 
the ImageIt lipid peroxidation dye. Live cultures were imaged using a fluorescence microscope for DsRed signals. 
Pictures were acquired at 40x magnification and scale bars indicate 100μm (Panel A). Flow cytometry analysis was 
conducted at the same time point for GBMs Line#2, NCH421k (Panel B) and shows overlay histograms of lipids 
(DsRed signal) at 24 hours for these GBMs. GBM treated with DMSO are represented in the black histogram, and 
CBD treated are red histograms. 
 
To confirm these findings, we turned to flow cytometry and found that CBD treatment decreased lipids in 
glioblastoma, as shown in the lipid MFI upon treatment. Interestingly the decrease in lipids was observed 
as early as 24 hours, time point at which massive CBD induced GBM death could not be quantified by flow 
cytometry. These changes were induced in both good- and low-CBD responders [Figure 4.22 panel B]. 
 
4.9. In mouse and human GBMs CBD acts as an antioxidant by decreasing water 
soluble ROS 
Since consistent lipid ROS increase or decrease were not observed upon CBD treatment, we continued the 
screening for water soluble general ROS using the dye H2-DCFDA (2',7'-dichlorodihydrofluorescein 
diacetate) [Keston S. et al (1965)].
Figure 4.23 In mouse (A) and human (B) GBMs CBD decreases water soluble ROS. Mouse and human GBM 
cells were treated with 0,01% DMSO or 10μM CBD for 20 hours and stained with H2-DCFDA for flow cytometry. 
Graphs indicate the mean +/- SEM of the percentage of ROS (DCF) positive cells in mouse (A) and human GBMs 
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(B) for 3 independent experiments. Two-tailed paired t test was used to evaluate the statistical significance 
comparing DMSO (gray bar) to CBD (green bar) treated cells for each GBM. 
 
Colorless H2-DCFDA dye diffuses into cell membranes and turns into DCF (2',7'-
dichlorodihydrofluorescein) when intracellular ROS oxidizes it, emitting green fluorescence [Berte N. et al. 
(2016)] proportional to intracellular ROS levels in GBMs. As a general outcome, we found that mouse and 
human GBMs exhibit different levels of ROS and that CBD significantly decreases ROS levels in all tested 
GBMs, regardless to their sensitivity to the drug [Figure 4.23].  
 
4.10. CBD induces mitochondrial changes in CBD-sensitive GBMs 
4.10.1. CBD increases mitochondrial superoxides in CBD-sensitive GBMs 
To complement the study of ROS in CBD induced GBM death we next turned to the mitochondrial 
compartment which is vital for energy generation in the form of ATP and the main cellular source of ROS 
in the form of superoxides (SOX). To specifically detect mitochondrial superoxides at a single cell level, 
we used the MitoSOX-red dye on live human GBMs by flow cytometry [Mukhopadhyay P. et al. (2007)]. 
Interestingly, we found that CBD treatment significantly increased MitoSOX levels in good-responders 
while exerting no significant changes in low-responders. [Figure 4.24]. 
Figure 4.24 CBD increases mitochondrial superoxides only in good-responders. GBM cells were treated with 
0,01% DMSO or 10μM CBD for 24 hours. The cell pellets were stained with MitoSOX-red and red fluorescence of 
the dye was acquired by flow cytometry. All gates were set using unstained controls for each GBM used and the gates 
were synchronized between unstained, DMSO, and CBD treated GBMs. The median fluorescence intensity (MFI) of 
positive cells was calculated for each gate and normalized to the number of positive cells (nMFI). The generated graph 
indicates the mean +/- SEM of the nMFI for DMSO (gray bar) and CBD (green bar) treated conditions. The 
experiment was repeated 3 to 6 times and the statistical significance of changes in mitochondrial superoxides was 
estimated with two-tailed paired t test. 
 
4.10.2. CBD tends to increase mitochondrial mass and MMP in human GBMs 
As significant changes in mitochondrial superoxides were observed in CBD-sensitive GBMs upon 
treatment, we investigated possible changes induced in the mitochondria themselves (mitochondrial mass). 
For this purpose, we used the MitoSpy-green, an equivalent to MitoTracker™ Green FM [Agnello M. et al. 
(2008)], as a mitochondrial localization probe that labels mitochondria independently of membrane 
potential. Mitochondrial mass was measured as green fluorescence positive signals by flow cytometry 
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[Pendergrass W. et al. (2004)]. There, we found a tendency towards an increase in mitochondrial mass upon 
CBD treatment [Figure 4.25-A].  
 
Figure 4.25 CBD induces changes in mitochondrial mass and membrane potential. GBM cells were cultured 
with 0,01% DMSO or 10μM CBD for 24 hours and stained with MitoSpy-green for mitochondrial mass (A) or 
MitoLite-Blue for MMP (B). Green and blue fluorescence intensities were detected by flow cytometry and the median 
fluorescence intensity (MFI) of positively stained cells determined. Graphs are representative of 3 independent 
experiments and show the MFI normalized to the number of positive events/cells (nMFI). For each GBM culture, the 
CBD treatment was compared to DMSO using two-tailed paired t test of mean +/- SEM.  
 
As the formation of MitoSOX is dependent on mitochondrial membrane potential (MMP) [Li R. et al. 
(2011)], we investigated potential changes in MMP after CBD treatment. We used MitoLite™ Blue FX490 
(MitoLite-blue), a cationic fluorogenic dye that utilizes the MMP to accumulate in mitochondria of live 
cells. Doing so, we found that CBD also tended to increase mitochondrial membrane potential in GBMs 
[Figure 4.25-B]. 
These data suggest that CBD treatment induces significant changes in GBM cell mitochondria in term of 
their mass, their membrane potential, and their production of superoxides.  
4.11. Antioxidants for GBM therapy: friend or foe? 
As we found that CBD could decrease the levels of water-soluble ROS, we tested the use of 7 pro-/anti-
oxidants as potential combination therapeutics to potentiate CBD cytotoxic effect. Two substances yielded 
consistent results: EGCG and NAC. EGCG (Epigallocatechin gallate) is the most abundant polyphenol 
found in green tea and is described as a potent oxidative stress regulator in cancer cells [Du G-J. et al. 
(2012)]. However, in certain context (iron Fe3+), EGCG may increase the production of hydrogen peroxides 
and act as a prooxidant [Kim H-S. et al. (2014)].  
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Figure 4.26 Redox regulators EGCG and NAC induce opposite effects on CBD induced GBM cytotoxicity. 
Human GBM cells were treated with DMSO, CBD and when evaluating the effect of EGCG 50μM EGCG, or 50μM 
EGCG and 10μM CBD or for NAC  5mM NAC, 5mM NAC+10μM CBD. The CytoToxFluor assay was carried out 
as previously described [Figure 4.9]. Graphs show the fold change of relative cytotoxicity compared to vehicle control 
for all conditions for the mean +/- SEM. One-way ANOVA with Bonferroni post-test was used to evaluate changes 
between different treatments: drug versus vehicle control (in black) or the CBD mono-treatment to the combination 
treatment of CBD with EGCG or NAC (in red). 
 
We evaluated the effect of this polyvalent redox regulator on human GBMs and found that EGCG 
systematically reduced CBD cytotoxicity [Figure 4.26-A]. Another antioxidant, used in several assays in 
vitro and in vivo as ROS quencher, N-acetyl-L-cysteine (NAC) [Mokhtari V. et al. (2017)] was also used as 
a potential candidate for CBD potentiation in vitro. At 5mM, NAC showed to be a good candidate to 
potentiate the cytotoxicity effect of CBD on human GBMs. Interestingly, NAC exerted a significant 
cytotoxicity effect when used alone; and systematically increased CBD cytotoxicity even in low-CBD 
responders (GBM13, NCH421k) [Figure 4.26-B].  
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4.12. The level of intrinsic antioxidant response of human GBMs determines 
their sensitivity to CBD  
4.12.1. CBD activates intracellular antioxidant systems 
Data from the basal flow cytometry screen for ROS levels upon CBD treatment and the cytotoxicity effects 
of the antioxidant NAC alone and in combination with CBD, suggest that ROS are important for the survival 
of GBM cells. Indeed, we showed that CBD acted as an antioxidant by decreasing the ROS levels in the 
GBMs, and that the antioxidant NAC exerted cytotoxicity in GBM cells and potentiated CBD effect [Figure 
4.26-B].  
To evaluate the intrinsic antioxidant response of GBMs, cells were co-transfected with luminescent reporter 
plasmids encoding an antioxidant response element promoter (ARE-firefly) + internal control 4.74 HSV-tk 
(renilla luminescence) or a minimal promoter control (4.27 firefly + 4.74 renilla luminescence).  At basal 
levels, we evaluated the extent of ARE activity in a good- and low-CBD responder. There, we found that 
the low-responder (GBM14) showed a significantly higher ARE activity compared to the good-responder 
NCH644 [Figure 4.27-A]. 
 
Figure 4.27 CBD increases antioxidant responses in human GBMs. GBM cells were co-transfected with 4.74-
hRluc (expression control) and either 4.27-luc2P (minimal promoter) or 4.37-luc2P (ARE). Five cultures of two stably 
transfected human GBMs (NCH644 and GBM14) were treated with 0,01% DMSO or 10μM CBD for 24 hours. ARE 
promoter activity was calculated as the ratio of firefly/renilla luminescence at basal level (A). Two-tailed paired t test 
was used to evaluate the statistical significance of the changes comparing DMSO to CBD conditions (B) for a same 
GBM (in black) and changes in antioxidant responses between CBD treated good-responder NCH644 to low-
responder GBM14 (in red) were evaluated using one-way ANOVA with Bonferroni post-test. 
 
After treatment, we found that CBD could increase the levels of ARE activity in both low- and good-CBD 
responders; however, the extent of increase was more important in the good- responder NCH644 than in 
NCH421k [Figure 4.27-B]. Here again our data suggest that although GBM cells an intrinsic basal level of 
antioxidant responses, they are still under oxidative stress. Also, we showed that levels of water-soluble 
ROS were decreased upon CBD treatment [Figure 4.23] which could be linked to CBD inducing the 
mobilization of cellular antioxidant systems [Figure 4.27-B].  
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4.13. NFkB signaling pathway is crucial to CBD induced GBM death 
4.13.1. Clues from mouse model of NFkB-p65 loss 
The transcription factor array revealed CBD increasing NFkB nuclear binding in the good responder line#2, 
as opposed to the low-responder NCH421k [Figure 4.21]. This prompted us to explore the NFkB pathway 
further. To study the importance of NFkB signaling in CBD induced GBM death, we examined the changes 
in CBD effect in the presence or absence of NFkB. We have previously shown that p53 mutant status of 
some mouse proneural GBMs influenced their sensitivity to CBD induced cytotoxicity, e. g. p53R1272H 
mutation combined with PDGFB [Figure 4.9]. To generate a proneural glioma mouse model of inducible 
p53R172H expression with concomitant p65 loss, we used a mouse model of Li-Fraumeni syndrome with 
inducible p53R172H mutation [Olive K. P. et al. (2004)] in combination with conditional p65 loss.  In this 
model, p53R172H mutated codons are preceded by LoxP sites flanking a STOP codon (Lox-STOP-Lox), 
assuring that the mutant p53 is not expressed without CRE mediated recombination [Tuveson D. A. et al. 
(2004)].  Concomitantly, the rel-a (p65) gene on chromosome 19 is also preceded by another set of LoxP 
sites flanking a STOP codon (Lox-STOP-Lox).  
 
 
Figure 4.28 Generation of proneural mouse model with mutant p53 status and NFkB-p65 loss. Mice were 
engineered for p53R172H (chromosome 11) and p65 (chromosome 19) preceded by Lox-STOP-Lox sites. NPC 
cultured were generated from SVZ of engineered mice, expanded, and transduced with recombinant viral vectors 
encoding CRE recombinase and PDGFB under biosafety level 2 conditions. The genetic recombinations to obtain the 
different models are indicated: p53R172H,p65 wt/wt-PDGFB (after viral transduction the cells express p53R172H, 
express wild type p65 from both alleles, and overexpress PDGFB), p53R172H,p65wt/L-PDGFB (after viral 
transduction the cells express p53R172H, have one functional allele of p65, and overexpress PDGFB), 
p53R172H,p65L/L-PDGFB (after viral transduction the cells express p53R172H, lose their p65 on both alleles, and 
overexpress PDGFB).  
 
We generated SVZ-NPC cultures from the genetically engineered mice and transduced the cells with viruses 
encoding CRE recombinase and PDGFB. This model was controlled using two other models of p53R172H-
PDGFB proneural glioma with two intact alleles of p65wt or only one functional allele [Figure 4.28]. 
The genotypes of the mice used for the models and the recombination have been re-verified by fluorescence 
microscopy for viral transduction efficiency. Recombination PCR was conducted for trp53 mutant and p65, 
46 
 
and we obtained after CRE recombination a band at the correct size of 330bp for trp53 mutant [Figure 4.29-
A1] and 1,7 kb for p65 deletion [Figure 4.29-A2].  
 
Figure 4.29 Characterization of generated mouse proneural glioma models with NFkB-p65 loss. SVZ-NPC 
cultures were generated from the genetically engineered mice and the cells were virally transduced to express CRE 
recombinase and PDGFB. To verify the virally induced genetic recombination, 106 cells from each model were 
pelleted and DNA extracted. PCR was carried out to verify the recombination at p53 (A1) and p65 (A2) loci followed 
by agarose gel electrophoresis. For p53 recombination, samples from the mouse tail and un-transduced NPCs (no 
recombination = no mutant band at 330bp) versus samples after CRE show a mutant band at 330bp (A1). 
Recombination PCR for p65 deleted band (1,7Kb) also comparing mouse tail, un-transduced NPC and CRE 
transduced NPCs (A2). A p65 genotyping PCR was conducted to detect p65flx band (300bp) or p65-wt band (270bp) 
in the 3 models (A3). Western blot was carried out to verify the modifications at the protein level for p53 and p65. 
Pancreatic ductal adenocarcinoma cells (PDAC) with known genetic background were used as control for blot 
detection of mouse cells with p65 wild-type allele, p65 truncated allele, and mutant p53. Hsp90 housekeeping protein 
was used as loading control (B1). Blots were quantified in ImageJ for expression of p65-wt, p65-truncated, and 
mutant-p53 for samples 2414 and 2408 by comparing the intensity of protein bands before and after CRE 
recombination and the value was normalized to that of the loading control HSP90 (B2).  
 
Genotyping PCR was conducted for p65 using DNA from all 3 mouse models before and after CRE 
recombination. For models with homozygous loxP sites around p65 loci (2408 and 2412), no wild-type band 
was detected, while wild-type (270bp) and floxed (300bp) bands were detected for 2414 with heterozygous 
p65 deletion [Figure 4.29-A3]. Western blot was performed to detect the changes at the protein level and 
show truncated band of p65 after CRE recombination along with mutant p53 bands in the samples [Figure 
4.29-B1].  The quantification of the blots clearly shows decreased p65wt expression, increased truncated 
p65, and increased p53-mutant expression after recombination. [Figure 4.29-B2].  
After the background genotype and the induced recombinations have been verified, the cytotoxicity effect 
of CBD was re-evaluated on the transgenic glioma models.  
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We found that the propensity of CBD induced cytotoxicity for the model with one allele of p65wt is 
comparable to the model with a full p65wt condition. However, when both alleles of p65 are deleted, the 
CBD induced cytotoxicity is significantly reduced. Therefore, intact p65 seems to play a critical role in CBD 
induced GBM death [Figure 4.30]. 
 
4.13.2. CBD induces NFkB-p65 nuclear translocation in drug sensitive GBMs. 
To confirm the importance of NFkB-p65 in CBD induced GBM death, we started by comparing Line#2 
(good-responder) to NCH421k (non-responder) for NFkB-p65 nuclear translocation upon treatment. Indeed, 
active NFkB complex is a nuclear complex composed most commonly of a heterodimer between the p65 
and p50 subunits. The subunits both have DNA binding sequences and p65 contains the transactivation 
domain of the complex which is used by IkB to retain the subunit in the cytoplasm. Upon activation, NFkB-
p65 is freed from its interaction with IkB and its nuclear localization signal is made available to direct its 
translocation to the nucleus [Ganchi P. A. et al. (1999)].  
 
Figure 4.30 Importance of NFkB-p65 for 
CBD induced cytotoxicity / mouse models. 
Mouse glioma cells with alterations in NFkB-
p65 were obtained after genetic 
recombination [Figure 4.30 &4.31] and used 
in quintuplicates in the CytoTox Fluor 
cytotoxicity assay for at least 3 independent 
experiments. The graph indicates the fold 
change of cytotoxicity compared to DMSO 
control with DMSO treated samples as gray 
bars, CBD treated samples as colored bars. 
Data are represented as mean +/- SEM and 
two tailed paired t test was used to compare 
CBD to DMSO treated cells for a same model 
(black stars) and one-way ANOVA with 
Bonferroni multiple comparison test (in red) 
was used when comparing the cytotoxicity of 
CBD in model with homozygous wild-type p65 (p65+/+) and the models with deleted alleles of p65 (p65+/- and 
p65-/-). 
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Figure 4.31 Immunofluorescence staining for NFkB-p65 nuclear translocation (group1). Human GBM cells 
good-CBD responder (Line#2) and a low-responder (NCH421k) were treated with DMSO or CBD for 20 hours. All 
wells were stained with rabbit anti-p65 primary antibody and nuclei counter stained with Hoechst 33342. Fluorescent 
pictures were acquired at 40x magnification and show from top to bottom the Hoechst staining (blue), the p65 (green) 
and the overlay of Hoechst and p65. Scale Bars = 150μm. 
 
Consistent with the transcription factor array, we found that CBD induced nuclear translocation of NFkB-
p65 only in Line#2. In the low-CBD responder, the levels of NFkB-p65 were already high at basal levels 
and tended to decrease upon treatment [Figure 4.31].  
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Figure 4.32 Immunofluorescence staining for NFkB-p65 nuclear translocation (group2). Cells plated in 8 well 
glass dishes coated with poly-ornithine and laminin were treated for 20 hours with 0,01% DMSO or 10μM CBD. 
Staining was conducted as previously [Figure 4.31]. The staining of a good-responder (NCH588J) and a low-
responder (NCH441) are shown; the figure shows from left to right the nuclei counterstained with Hoechst 33342 
(blue), p65 staining (green), and the overlay of nuclei and p65 staining with a 150% enlargement showing a closer 
image of the nuclei. For each GBM, the DMSO treated cells are on top and the CBD treated on the bottom. White 
scale bars indicate 100μm, and gray scale bars for the zoom indicate 25μm. 
 
We enlarged the screening panel to obtain 3 responders versus 3 low-responders. Again, the finding was 
confirmed. We concluded that CBD induced GBM death does not occur if NFkB-p65 is not functional to 
be translocated to the GBM nuclei [Figure 4.32]. 
Figure 4.33 CBD treatment increases the nuclear accumulation of NFkB-p65 only in good-CBD responders. 
p65 immunofluorescence antibody staining and pictures acquisition were conducted as described previously [Figure 
4.34]. The graph indicates the percentage of positively stained nuclei in DMSO (gray bar) and CBD (colored bar) 
treated GBMs. Three good-responders (Line#2, NCH644, GBM20) and 3 low-responders (NCH421k, NCH441, 
GBM14) were used.  Two-paired t test statistical analysis was conducted comparing the mean +/- SEM of CBD 
(colored bars) to DMSO (gray bars) treated cells. 
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We quantified the staining for at least 3 independent experiments and found that CBD significantly increased 
nuclear translocation of p65 only in good-CBD responders (Line#2, NCH644, GBM20), while no significant 
changes were seen in low-responders (NCH421k, NCH441, GBM14) [Figure 4.33]. 
4.13.3. CBD decreases TNFα induced NFkB promoter activity 
4.13.3.1. TNFα can induce NFkB promoter activity only in good-CBD responders 
As nuclear translocation was observed in responders, we checked the capacity of CBD to induce NFkB 
promoter activation in a promoter activation reporter assay. The reporter plasmid contains a destabilization 
domain (DD) which in the absence of the small molecule Shield1 will target the reporter fluorescence for 
proteasomal degradation [Banaszynski L. A. et al (2006)]. When Shield1 was applied with DMSO, we could 
monitor the basal NFkB promoter activity in the GBMs and compare it to the CBD treated cells. TNFα was 
used as positive inducer of NFkB promoter activity [Poligone B. et al (2001)].  
 
Figure 4.34 Evaluating the effect of CBD on GBM NFkB promoter activity. Human GBM cells stably transfected 
with the pNFkB-DD-ZsGreen1-neo reporter plasmid were exposed to 3 treatment conditions after addition of 
stabilizing molecule Shiled-1: 0,01% DMSO, 10μM CBD, or 10ng/ml of TNFα. A panel of 3 good-(Line#2, NCH644, 
GBM20) and Low-(NCH421k, NCH441, GBM14) CBD responders was used. After 20 hours of incubation, wells 
were inspected for green fluorescence as a reporter for NFkB promoter activation. Images were acquired in a 
fluorescence microscope at 40x magnification. Scale bars = 100μm. 
 
We found that CBD did not induce an increase in NFkB promoter activity in the responders. In the non-
responders NH421k and NCH441 no changes where observed as well and not even when using TNFα. The 
non-responder GBM14 already had a high basal level of NFkB promoter activity that did not change upon 
CBD or TNFα treatment. Unexpectedly, only in good-CBD responders could TNFα induce promoter 
activation [Figure 4.34]. 
 
4.13.3.2. CBD decreases TNFα induced NFkB promoter activity 
We turned to flow cytometry to quantify the changes in NFkB promoter activity at the single cell level, 
starting with the good-CBD responder Line#2. 
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Figure 4.35 CBD decreases TNFα induced NFkB promoter activation. Line#2 stably transfected with pNFkB-
DD-Zsgreen1-neo reporter plasmid was treated with TNFα at 0-, 1-, 2-,4-,8-,10-,20-,30-,40-, and 50 ng/ml. After 24 
hours, green fluorescence reporter of NFkB promoter activity was acquired by flow cytometry. The graph shows the 
mean +/- SEM of the percentage of cells positive for NFkB promoter activity for 3 independent experiments (Panel 
I). The effect of CBD treatment on TNFα induced NFkB promoter activation was evaluated in Line#2. Flow 
cytometric density plots of Line#2 treated with a combination of shield and DMSO, CBD, TNFα, TNFα+CBD are 
represented in Panel II. The effect of CBD pre-treatment (1-, 3-, 6-, 16 hours) on promoter activation was measured 
by flow cytometry. The percentage and median fluorescence intensity (MFI) of cells with active NFkB promoter are 
indicated in Panel B.  
 
Density FACS plots show no induction of promoter activity when Line#2 is treated with Shield+DMSO or 
Shield+CBD. Upon TNFα treatment cells accumulate in the positive gate and we observe a decrease in this 
accumulation when cells receive CBD and TNFα [Figure 4.35-A]. To evaluate the inhibitory role of CBD 
on NFkB promoter activation, we pre-treated a good CBD responder Line#2 with CBD for 1-, 3-, 6-, or 16 
hours before applying TNFα. At all considered time points, pre-treating Line#2 with CBD before adding 
TNFα for 24 hours reduced the promoter activity [Figure 4.35-B]. 
 
We enlarged the screening to other good- (NCH588J, NCH644, Line#11, GBM20) and low- (NCH421k, 
NCH441, GBM13) CBD responders, and came to the same conclusion. Although CBD induces NFkB-p65 
nuclear translocation in good-CBD responders [Figure 4.33], it does not induce NFkB promoter activity, 
but decreases promoter activation induced by TNFα [Figure 4.36]. 
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Figure 4.36 Only in good-CBD responders does CBD decrease TNFα induced NFkB promoter activation. GBM 
cells, good- (NCH588J, NCH644, Line#11, GBM20) and low- (NCH421k, NCH441, GBM13) CBD responders, were 
subjected to 4 treatment conditions: 500nM Shield + 0,01% DMSO (SD), 500nM Shield + 10μM CBD (SC), 500nM 
Shield + 1ng/ml TNFα (ST), or pre-treated with 10μM CBD for 6 hours then incubated with 10μM CBD for 20 hours 
(SCT). Green fluorescence of the pNFkB-DD-ZsGreen1 plasmid in cells with active NFkB promoter was measured 
by flow cytometry. Graphs show the mean +/- SEM of percentage of cells with active promoter activity. Two-tailed 
paired t test was used to evaluate the changes between ST treatment condition and SCT condition. 
 
 
In low-CBD responders, both TNFα and CBD failed to induce NFkB promoter activity. In one low-
responder, GBM13, we found a significant increase in promoter activity when TNFα and CBD are used in 
combination, but it is probably due to the low variability observed in this sample. 
4.13.4. The NRF2 activator DMF potentiates CBD induced cytotoxicity 
We have shown that although functional NFkB-p65 is needed for CBD induced GBM death [Figure 4.33], 
CBD treatment does not induce NFkB transcriptional activity, but rather decreases TNFα induced NFkB 
promoter activation [Figure 4.36]. Also, we showed that antioxidant response elements (ARE) are active at 
basal level in GBMs and that CBD treatment, while decreasing water-soluble ROS [Figure 4.23], 
significantly increases ARE activity in good- and low-CD responders [Figure 4.27]. Therefore, increasing 
antioxidative response in GBMs seems to be detrimental to GBM survival. Dimethyl fumarate (DMF) is a 
clinically approved antioxidant, that activates NRF2 pathway. It is used for the treatment of multiple 
sclerosis and psoriasis [Wang Q. et al. (2015)] and was shown to decrease the expression of stem cell marker 
CD133 and NFkB in glioblastoma and to inhibit the transcription of inflammatory cytokines such as IL6 
and TNFα [Ghods A. L. et al. (2013)]. We tested the effect of DMF on a CBD sensitive GBM Line#2 in 
MTT and cytotoxicity assays.  
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Figure 4.37 DMF potentiates CBD cytotoxicity in a combination therapy of GBM-Line#2. Line#2 (good-CBD 
responder) was used to test the effect of Dimethyl fumarate (DMF) used a mono-treatment or in combination with 
CBD in a MTT assay and cytotoxicity assay.  Cells were treated for 72 hours for the MTT assay and for 20 hours for 
the cytotoxicity assay. Treatment conditions were either 0,01% DMSO, 10μM CBD, 10μM DMF, or co-treated with 
10μM CBD + 10μM DMF. The absorbance was recorded for the MTT assay whereas the fluorescence intensity was 
measured for cytotoxicity assay. Graphs were generated for both assays and indicate the fold change in 
viability/proliferation (left) and cytotoxicity (right) induced by CBD and/or DMF compared to vehicle control. The 
experiments were repeated 3 times and two-tailed paired t test of mean +/- SEM was used to compare the different 
treatments to DMSO control (black stars) and One-way ANOVA with Bonferroni post-test comparing CBD to 
CBD+DMF (red). 
 
In good-CBD responder Line#2, DMF alone already decreased the viability of the cells and increased their 
death. Combining DMF and CBD, significantly increased CBD cytotoxicity in this GBM [Figure 4.37]. 
Therefore, DMF might be a good candidate to potentiate antioxidative cytotoxicity effect of CBD in GBMs. 
4.14. Evaluation of a patient stratification scheme for beneficial CBD therapy 
4.14.1. Sets of genetic alterations qualifying for successful CBD therapy 
To evaluate if GBM genetic alterations could be used to predict their response to CBD treatment, we started 
by comparing the outcome of the cytotoxicity assay for the genetically engineered mouse models [Figure 
4.9]. These glioma models bear either loss or mutation of tumor suppressors (p53, cdkn2a, PTEN, NF1), 
and overexpress oncogenes (PDGFB, EGFR/EGFRvIII) [Figure 3.1]. 
The cytotoxicity assay allowed us to categorize the mouse gliomas into low- and good-CBD responders, 
and we used their genetic make-up to evaluate a stratification scheme predicting CBD response. We found 
that classical mouse gliomas were always sensitive to CBD (4 to 10-fold cytotoxicity), depending on genetic 
alterations, some proneural mouse gliomas were very sensitive (e.g. p53R172H-PDGFB) whereas other are 
less sensitive (e. g. cdkn2aKO-PDGFB) [Figure 4.9]. Therefore, a stratification based only on the genetic 
subtype would not be accurate. Therefore, we ought to find a more reliable stratification strategy. 
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4.14.2. Metabolic markers to predict the outcome of CBD mediated GBM therapy 
4.14.2.1. In vitro, basal ROS levels inversely correlate with the extent of CBD induced GBM 
death 
We showed that CBD treatment decreased ROS in mouse and human GBMs regardless of CBD sensitivity, 
we wanted to discover if we could differentiate between prospective CBD sensitive and insensitive GBM 
subsets before any treatment. GBMs were taken at basal levels without any treatment and stained for water 
soluble ROS using the cell permeant-H2DCFDA dye. Quantitative flow cytometry was performed to obtain 
the molecules of equivalent fluorescein (MEFL) of DCF positive GBMs.  
 
 
 
Figure 4.38 CBD cytotoxicity inversely correlates with basal GBM ROS levels. Human GBMs were stained with 
H2-DCFDA, washed and immediately acquired by flow cytometry. Rainbow calibration particles (RCP) of known 
concentration of molecules of equivalent fluorescein (MEFL) were acquired using the same laser settings. The median 
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fluorescence intensities (MFI) of DCF positive GBMs and RCP were determined in positive gates. The MFI of DCF 
positive GBMs was used to calculate their molecules of equivalent fluorescein (MEFL) based on the MFI of the RCPs 
with known MEFL. The generated graphs show the linear regression comparing the MFL of DCF positive GBMs to 
their fold change (FC) of CBD induced cytotoxicity (A and B). The MFI normalized to number of positive cells 
(nMFI) was also compared to the fold change of CBD induced cytotoxicity (C).  Correlation analysis was conducted 
for all comparisons and summarizes in a table the 95% confidence interval, the p value and the R squared. 
 
Linear regression analyses showed that levels of ROS inversely correlate with the fold change of 
cytotoxicity induced by CBD [Figure 4.38 A, B]. Because of two different instruments settings and more 
than one-year elapsed time between the two rounds of measurements, two different correlation graphs were 
generated. Therefore, we also normalized MFI of ROS in all GBMs (nMFI) were plotted in a single graph 
and again compared to CBD induced cytotoxicity, and we again found a significant inverse correlation 
between basal ROS level and putative CBD sensitivity [Figure 4.38 C]. 
 
4.14.2.2. Basal ROS levels can serve as predictive biomarker for CBD response in ex vivo GBM 
biopsies 
We engaged in translating our in vitro findings to a setting that could be applied in the clinics, by 
performing ex vivo measurements of ROS in patient derived GBM xenografts from mouse brains in bulk 
tumor tissue or in xenograft single cell suspension. 
4.14.2.2.1. Measurement of ex vivo ROS in bulk tumor tissue 
 
Figure 4.39 GBM ROS can be detected ex vivo in bulk tumor tissue. Staining of bulk biopsy and detection of 
intracellular ROS. The tumor was localized on the right hemisphere and dissected from nude mice brain. The tumor 
mass was chopped into 2mg pieces, and tumor tissue inoculated with H2DCFDA ROS dye. The bulk tumor tissue 
was surrounded by 2 glass coverslips and the ROS fluorescence imaged in the intraoperative system (IOS) and 
compared to the unstained tissue. The color scale indicates the extent of ROS detection from dark blue (no 
fluorescence detected) to bright yellow (the most intense fluorescence detected).  
 
To evaluate the suitability of the intraoperative system (IOS) for our detection purpose, we first tested bulk 
tumor biopsies comparing unstained to H2DCFDA (intracellular) ROS dye. There, we showed that 
intracellular ROS could be detected in bulk GBM tissue, but proper quantification would be difficult because 
of uneven dye distribution in the tumor tissue [Figure 4.39]. Therefore, we tested the use of cells and/or 
mashed biopsy suspension in the IOS.  
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4.14.2.2.2. Basal GBM ROS measurement is reliable across different platforms  
The ex vivo measurement of basal ROS levels was conducted in different platforms and different 
combination of low- and good-CBD responders in the IOS using tubes or glass capillaries, in fluorescence 
spectroscopy using another water-soluble ROS dye (MAK-142) and in flow cytometry (H2-DCFA).  
 
Figure 4.40 Ex vivo, low basal ROS levels are associated with good prospective CBD response. Basal ROS 
measurements comparing low- (NCH421k / GBM14) versus good- (Line#2 / NCH644) CBD responders - from left 
to right - in the IOS (panel A), fluorescence spectroscopy (panel B) and flow cytometry (panel C). In the IOS, ex vivo 
GBM biopsies of Line#2 and NCH421k were stained with H2-DCFDA, loaded in glass capillaries, and their 
fluorescence compared to unstained samples. GBM14 and NCH644 cultured cells were stained with H2-DCFDA, 
loaded in 1,5ml tubes and measured in the IOS. Another water-soluble ROS dye (MAK-142) was used in fluorescence 
spectroscopy for ex vivo mashed human GBM biopsies comparing the dye alone (red wave), Line#2 (blue wave), and 
NCH421k (purple wave). In flow cytometry, ex vivo mashed GBM biopsies of good CBD responders (Line#2, 
NCH644) and low CBD responders (NCH421k, GBM14) were measured for their DCF fluorescence. The median 
fluorescence intensity of positive event was determined and normalized to the number of cells (nMFI). Each point on 
the graph represents an individual tumor from one mouse and the mean +/-SEM of the ROS nMFI for the independent 
experiments is shown. 
 
In all cases, we found good-CBD responders having lower levels of ROS fluorescence compared to good-
CBD responders [Figure 4.40]. This is consistent with our in vitro data for H2-DCFDA staining where we 
showed an inverse correlation between the water-soluble ROS levels and the prospective CBD response 
[Figure 4.38]. The measurement of ex vivo GBM biopsies for their ROS levels could easily be translated to 
the clinics to predict a tumor sensitivity to CBD treatment. 
4.15. In vivo, CBD prolongs the survival of mice bearing CBD sensitive patient 
derived GBMs 
To verify our in vitro data, postulating the differential impact of CBD on GBMs, we implanted mice with 
low- and good-CBD responding GBMs of human (NCH421k, Line#2) and mouse origin (Cdkn2aKO-
PDGFB, p53R172H-PDGFB). We found that in mice bearing good-responders, CBD had a positive impact 
on survival compared to the vehicle treatment.  
 
The statistical significance of in vivo CBD therapy was evaluated for mouse and human GBMs.  
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Figure 4.41 Analysis of overall survival of CBD treated mice.  Mice with human (Line#2, NCH421k) or mouse 
gliomas (p53R172H-PDGFB, cdkn2aKO-PDGFB) were treated daily intraperitoneally with 1μl/g of freshly mixed 
vehicle (0) or CBD (15mg/kg) in tween80-NaCl. The overall survival was evaluated using Kaplan-Meier estimation 
with median survival for each treatment group and the p-value. Survival of vehicle treated mice is indicated in blue 
and those of CBD treated mice is indicated in red. Mice bearing mouse gliomas are in the top panel and mice with 
human GBM are in the bottom panel. Low-CBD responders cdkn2aKO-PDGFB (mouse) and NCH421k (human) are 
on the left side of the figure and show no benefit to the treatment, whereas good-CBD responders p53R172H-PDGFB 
(mouse) and Line#2 (human) are on the right side of the figure and treated groups showed prolonged survival.  
 
Trials of human (Line#2 and NCH421k) and mouse cohorts (Cdkn2aKO-PDGFB and p53R172H-PDGFB) 
confirmed beneficial CBD effect for mice bearing good-CBD responders [Figure 4.41-right], whereas 
cohorts of low-CBD responders did not benefit from the treatment [Figure 4.41-left].  
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5. Discussion 
It has previously been shown that vanilloids secreted by NPCwt have the capacity to kill gliomas [Stock K. 
et al. (2012)]. Here, we confirmed the ability of endovanilloids from NPCwt to induce cytotoxicity in a 
selection of genetically engineered mouse glioma models while sparing NPCwt, which is encouraging for 
clinical use of vanilloids. 
One potential candidate to the clinical application of vanilloids is the plant derived vanilloid CBD, which is 
advanced to phase IIb of clinical trials for the treatment of glioblastoma. In human GBMs and in genetically 
engineered mouse gliomas mimicking genetic alterations described in human GBMs, we showed that CBD 
induced cytotoxicity to different extent. We categorized our panel of GBMs into low- and good-CBD 
responders. Depending on the genetic background of the gliomas (human or mouse) we were able to pinpoint 
sets of genetic alterations that are associated with CBD sensitivity. These include classical GBM subtype 
with EGFRVIII overexpression or proneural GBM subtype with cdkn2a loss and PDGFB overexpression. 
Interestingly and in accordance with current literature, we showed that CBD selectively killed glioma cells 
without affecting the viability of NPCwt [Shrivastava et al. (2011)]. Therefore, CBD would not be toxic to 
healthy NPC when used in vivo. 
We determined the cell death mode induced by CBD and found that GBMs with wt-p53 die in a caspase 
dependent manner as their cell death is blocked by the pan-caspase inhibitor Q-VD-Oph. GBMs with a 
mutant p53 were not affected by the inhibitor. Using a newly established flow cytometry panel we revealed 
that mutant-p53 GBMs mainly die via autophagy. Some p53wt GBMs also showed sensitivity to autophagic 
cell death, highlighting that CBD could induce more than one death pathway in glioblastoma. Numerous 
studies showed that cannabinoids and CBD in particular could induce apoptosis or autophagy induced 
apoptosis in glioma cells [Fisher T. et al. (2016)]. However, we were able to screen the effect of CBD on a 
large panel of patient derived glioblastoma and to link the p53 status to the predominant cell death mode 
induced by CBD. 
CBD was previously shown to shift cancer cell metabolism [Kalenderoglou N. et al. (2017)] but there is a 
scarcity of reports regarding metabolic profiling of its effect on patient derived GBMs. In our study we 
characterized the metabolic impact of CBD on human and mouse GBMs using NMR and showed that there 
was a clear separation between DMSO and CBD treated gliomas. Also, we detected similar trends in 
metabolic alterations between mouse and human such as decrease in energy levels in the form of ATP, 
aminoacids. Which suggest that CBD could metabolically slow down the GBM cell metabolism as less ATP 
is available upon treatment.  
CBD is a lipophilic compound and needs to be solubilized in hydrophobic carriers [(Zgair A. et al. (2016)]. 
Independently from its solubility and bioavailability, Olar and collaborators showed CBD exerting a 
sebostatic effect via activation of TRPV4. This resulted in an inhibition of the ERK/MAPK pathway. 
Therefore, CBD is considered a good candidate in the treatment of acne vulgaris [Olar A. et al. (2014)]. In 
the transcription factor array we showed that CBD could alter factors implicated in de novo lipid synthesis 
in GBMs. We corroborated this finding in a microscopy study of a panel of good- and low-CBD responders 
and found that in both cases CBD altered the distribution of lipids at the plasma membrane of human GBMs. 
Our finding is in accordance with the study of Villa et al. showing GBM being highly dependent on 
cholesterol for survival. By inhibiting cholesterol uptake, they could successfully decrease GBM size in 
vivo and prolong the survival of the mice [Villa G. R. et al. (2016)]. However, as CBD decreased lipids in 
both low- and good- responders, this cannot be used as a stratification strategy. 
While screening for the cell death mode induced by CBD, we found that combining CBD treatment with 
the lipid peroxidation inhibitor Ferrostatin-1 could significantly reduce CBD induced GBM death, 
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suggesting the importance of lipid peroxidation in CBD induced GBM death. However, this finding could 
not be confirmed when we specifically looked at lipids and their peroxidation (ratio of lipid 
hydroperoxides/lipids). Besides lipid related reactive oxygen species, we evaluated water soluble ROS and 
found that CBD had the capacity to reduce water soluble ROS in mouse and human GBMs, regardless of 
their sensitivity to CBD treatment. This prompted us to consider CBD having antioxidant properties in 
GBMs to the contrary of what some previous studies have shown. Indeed, Singer et al. described CBD 
exerting its cytotoxicity effect on a selection of GSCs by increasing the levels of ROS which later induced 
CBD resistance in these tumor cells [Singer E. et al. (2015)]. In 2015, Scott al. also showed CBD increasing 
ROS and concomitantly HSPs at the gene and protein levels in GBMs. Although our data disagree with 
these findings, a more recent study did show CBD as an antioxidant drug with ROS scavenging properties 
and neuroprotective effects against oxidative stress insults in a hippocampal neuron injury model [Sun S. et 
al. (2017)].  
Although our data on CBD decreasing water soluble ROS seems in opposition with some published studies, 
we also found that CBD could indeed induce ROS increase in GBMs when considering a specific type of 
ROS namely mitochondrial superoxides (MitoSOX). We showed that only in good- CBD responders, 
exposure of these GBM to CBD for 24 hours significantly increased MitoSOX levels while also inducing 
changes in mitochondrial mass and membrane potential. This is in opposition with previous studies showing 
CBD decreasing mitochondrial SOX and membrane potential. CBD-induced apoptosis was linked to its 
ability to target voltage dependent anion channel 1 (VDAC1) at the mitochondrial outer membrane in 
microglial cell line BV2 [Rimmerman N. et al (2013)]; and in breast cancer cells, CBD was shown to 
decrease mitochondrial membrane potential while inducing autophagy and apoptosis [Shrivastava et al. 
(2011)] and [Massi P. et al. (2013)]. Altogether, these studies highlighted an impact of CBD on mitochondria 
in the protection of healthy and the dismissal of deleterious cells.  
The antioxidant effect of CBD on mouse and human GBMs prompted us to broaden our screen to potential 
therapeutics that could be used to potentiate CBD effect. The high metabolic rate of GBMs and their high 
levels of ROS drove us to screen the effect of other pro- and anti-oxidants especially N-acetyl-L-cystein 
(NAC) and epigallacto-catechine-gallate (EGCG). NAC was also shown to inhibit TNFa induced NFkB 
activation by suppressing IkappaB and NFkB-inducing kinases [Oka S. et al. (2000)]. EGCG was shown to 
inhibit NFkB pathway by promoting NRF2 dissociation from Keap1. Nuclear translocated NRF2 induces 
ARE genes that inhibit NFkB activation [Jiang J. et al. (2012)]. However, in our experiments we obtained 
opposing results with these two antioxidants. EGCG consistently decreased CBD induced death in GBMs 
whereas NAC, a well-established ROS quencher, consistently increased CBD induced death while already 
showing cytotoxicity effect on its own. Our data on NAC effect on GBMs is corroborated by the study of 
Monticone et al. demonstrating the efficacy of NAC and other antioxidants in decreasing GBM viability 
and impairing cell cycle progression [Monticone M. et al. (2014)]. However, more explorations will be 
needed to shed light on the mechanism of action of these two antioxidants and discover why they have such 
distinct effects on CBD induced GBM death. 
Vanilloids were previously shown to kill gliomas via the induction of ER stress induced apoptosis [Stock 
K. et al. (2012)]. We confirmed ER stress induction in patient derived GBMs using the ER stress activation 
profiling plate array and pinpointed differentially ER related transcription factors between low-CBD 
responder NCH421k and good-CBD responder line#2. Trends of alterations in these differentially regulated 
transcription factors were also corroborated by other assays for example when showing CBD decreasing 
lipid metabolism which was also corroborated by other published studies [Villa G. R. et al. (2016)]. We also 
showed some interesting alterations in transcription factors implicated in redox homeostasis and 
inflammation such as NRF2 and NFkB. The increase in NRF2 observed was in line with our finding that 
CBD acts as an antioxidant by decreasing water soluble ROS levels in GBMs.  
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One interesting transcription factor differentially regulated between low- and good-CBD responders in the 
TF array was NFkB. In good-CBD responder Line#2, we showed that CBD increased the nuclear binding 
of NFkB-p65 to TNIP1 consensus sequence used in the array. We confirmed this CBD-induced nuclear 
shuttling by immunofluorescence staining for the NFkB-p65 and observed that its nuclear translocation was 
increased by CBD only in good-CBD responders. As NFkB is routinely described as a promoter of tumor 
cell survival and proliferation [Masilamani A. P et al. (2017)] and [Soubannier V. et al. (2017)], we found 
our data in opposition with the literature. Activated NFkB signaling was even proposed to play a role in the 
establishment of glioma by promoting the differentiation of cancer stem cells with constitutive NFkB 
activation [Widera D. et al. (2008)]. Indeed, it is described in the case of glioblastoma that inactivation of 
NFkB and other pathways such as ERK/MAPK is important for glioblastoma apoptosis [Liu P. C. et al. 
(2017)]. Results from our mouse model of NFkB-p65 loss showed the importance of p65 in CBD induced 
GBM death as mouse proneural gliomas with homozygous loss of p65 lose their sensitivity to CBD induced 
cytotoxicity. This important role of NFkB-p65 in CBD mediated death prompted our interest to uncover 
which action was p65 carrying out in GBM nuclei upon CBD induced translocation. In our NFkB promoter 
activation reporter assay, we showed that although CBD selectively induces p65 translocation in good-
responders, it does not induce NFkB promoter activity. In fact, we showed that in good-CBD responders, 
CBD treatment could significantly decrease TNFα induced NFkB promoter activation. Therefore, CBD 
induced translocation would promote a blockage of NFkB transcriptional activity instead of a detrimental 
activation.  A recent study of Hackler et al. supports in many ways our findings in that the antioxidant 
curcumin (C-150) which also shows anti-inflammatory properties, induced profound cytotoxicity in glioma 
cells by inhibiting the transcriptional activity of NFkB [Hackler L. Jr. et al. (2016)]. Further investigations 
will be needed to discover the exact molecular pathways induced in the nuclei of dying GBMs upon CBD 
treatment; may it be p65 translocation-binding and blocking the access of NFkB promoter for activation or 
the re-distribution of p65 to other nuclear territories such as the nucleolus, where p65 has been shown to 
induce cell death after inducing nuclear export of nucleophosmin (NPM) and mitochondrial mobilization 
for cell death induction [Khandelwal N. et al. (2011)]. Moreover, the nucleolus is now specifically being 
considered in novel cancer therapeutic strategies as it was shown to be dysregulated in many cancers and 
playing a crucial role in NFkB regulation of tumor death [Chen J. et al. (2017)]. 
The main transcription factor balancing NFkB effect is NRF2, which signaling pathway is the main system 
controlling redox homeostasis in all cells. They both exert reciprocal feed-back loops to balance their effects 
and balanced activation of NFkB and NRF2 is mandatory to assure proper control of inflammation and 
oxidative damage [Wardyn J. D. et al. (2015)]. In a selection of patient derived glioblastoma, one low-
responder versus one good-responder, we showed that at basal level, GBM cells have active NRF2/ARE 
pathway activity, with the low-responder showing higher levels of oxidative stress compared to the good-
responder. Upon CBD treatment we obtained in both cases an increase in antioxidant responses, further 
supporting our data on CBD antioxidant properties. However, the shift in antioxidant response in the low-
CBD responder was lower compared to the good-CBD responder. As we showed that CBD rather induced 
an inhibitory effect on NFkB transcriptional activity we realized that these two master regulators are again 
brought to collaboration by CBD. Although NFkB has been described in numerous studies to promote the 
production of ROS, other studies demonstrated an anti-oxidative role of NFkB by promoting the 
transcription of certain antioxidant proteins. The most famous target of NFkB antioxidant activity is 
manganese superoxide dismutase (MnSOD), a mitochondrial antioxidant which induces the conversion of 
MitoSOX (O2.−) into water soluble ROS hydrogen peroxide (H2O2) [Morgan M. J. et al. (2011)]. Although 
we did observe reduction in water soluble ROS upon CBD treatment, we cannot adhere to the concept that 
NFkB would be involved in promoting antioxidant activity in GBMs because we could not show any 
induction of promoter transcriptional activity. Therefore, we assumed that CBD effect on water soluble ROS 
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levels and NFkB-p65 could be two distinct effects of CBD ultimately leading to GBM death. When we 
consider CBD reducing ROS in both good- and low-CBD responders, we would be inclined to think that 
the cytotoxicity effect of CBD is not linked to its impact on ROS levels. But when we add the selective 
effect of CBD on increasing MitoSOX levels we are driven back to the importance of ROS in CBD induced 
GBM death. It might be that the cellular antioxidant machinery was mobilized for a first round of ROS 
decrease but a second increase in MitoSOX, selectively in good-CBD responders, would generate more 
water-soluble ROS, that would overwhelm cellular antioxidant systems. This situation leading to 
accumulation of new ROS could oxidize translocated p50-p65 complexes thus leading to destabilization of 
DNA binding and changes in specific phosphorylation of p50 serines and chromatin remodeling processes 
required for adequate transcriptional activity [Zhang J. et al. (2016)] and [Morgan M. J. et al. (2011)]. CBD 
is a pleiotropic drug that affects multiple interconnected signaling pathways. The challenge of future studies 
will be to clarify a step further the variations of NFkB nuclear modifications in the form of phosphorylation, 
binding capabilities and intranuclear territory localization that could directly play a role in CBD mediated 
GBM therapy. 
As NFkB and NRF2 pathways are mutually regulated, and we found that NFkB was not transcriptionally 
active, but important in CBD induced GBM death, we ought to look at the NRF2 pathway deeper. NRF2 
inducer dimethyl fumarate (DMF) [Gopal S. et al. (2017)] and [Galloway D. A. et al. (2017)] significantly 
increased CBD induced GBM death in one CBD responder. Therefore, DMF could be considered a good 
candidate to GBM CBD combination therapy. Indeed, DMF has been shown to sensitize lymphoma cells to 
apoptosis via NFkB targeting [Nicolay J. P. et al. (2016)], to induce breast cancer cell death by covalent 
binding of NFkB-p65 and inhibiting transcriptional activity [Kastrati I. et al. (2016) and Kastrati I. et al. 
(2017)]. Also, there is already a phase I GBM clinical trial involving DMF, radiotherapy and temozolomide, 
where DMF is used to sensitize GBM cells to radiotherapy [Shafer D. A. et al. (2017)]. In any case, further 
investigations should be conducted on CBD combination therapy not only using DMF but also promising 
antioxidants such as NAC and other phytovanilloids. 
To support ongoing CBD clinical trials and their successful outcome, showing induction of cytotoxicity in 
multiple GBM cells is not sufficient. Indeed, such a simple screen, does not help in trial enrolment selection 
and future therapeutic decisions where patient stratification for prospective drug response is crucial. 
Therefore, we extensively screened our palette of human and mouse GBMs and described 2 options for 
patient stratification for beneficial CBD therapy. The first one considers sets of genetic alterations that we 
found associated with CBD sensitivity such as proneural GBMs with p53 hot-spot mutations in the DNA 
binding domain or GBMs of the classical subtype with EGFR/EGFRvIII overexpression. We also 
highlighted genetic signatures associated with poor CBD sensitivity such as dual loss of p53 and NF1. The 
second stratification scheme we propose is based on GBM ROS levels as metabolic marker of CBD 
sensitivity. In our in vitro screen of all human GBMs, we showed that the lower the ROS levels of GBMs 
without any drug treatment, the higher the prospective response to CBD. To move our experiments a step 
closer to possible clinical applications, we performed basal ROS measurements on ex vivo human tumor 
biopsies from athymic nude mice. Aiming to find a straightforward method to predict CBD sensitivity for 
clinical patient biopsies, we corroborated our in vitro results with the ex vivo experiments across 3 
measurement platforms (glass capillaries in the IOS, fluorescence spectroscopy, and flow cytometry) to 
obtain qualitative and quantitative results. To validate the application of this simple method to predict CBD 
sensitivity in human GBMs, we would need to enlarge our screening pool and, in the future, collaborate 
with neurosurgical departments either agreeing to deliver fresh biopsies as they perform biopsies or surgical 
resections, or sharing with them the protocols to detect the basal ROS levels onsite. 
Our in vitro cytotoxicity screening data were verified in in vivo experiments where we compared CBD effect 
in mice bearing a low- versus good-CBD responders. Indeed, no beneficial effect was seen in the low-CBD 
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responders whereas good-CBD responders showed significantly increased survival compared to vehicle 
treated mice. The good-CBD responder Line#2 showed to be very aggressive when we visually inspected 
the tumor brains at humane end-point in the vehicle treated mice. The last mouse of the vehicle died about 
25 days earlier than the last mouse of the CBD treated group. It would be interesting to enlarge the cohorts 
of mice bearing human GBMs with known CBD sensitivity in vitro and validate the CBD effect in vivo. 
Also, a trial of immunocompetent mice bearing genetically engineered mouse gliomas of known CBD 
sensitivity corroborated the message of our in vitro screens showing CBD differentially inducing 
cytotoxicity in GBMs depending on their genetic backgrounds. Another interesting approach of in vivo 
studies would be to consider treating GBM bearing mice at different stages of tumorigenesis and evaluate a 
time point of best drug efficacy. Equally, in vivo evaluation of other therapeutics such as other vanilloids or 
antioxidants that could be used to potentiate CBD effect would also be interesting. 
Clinical trials of CBD for several diseases are already ongoing. Epidiolex® is a pure CBD oral solution in 
Phase III clinical trials for the treatment of epileptic seizures in Lennox-Gastaut syndrome (one trial) and 
Dravet syndrome (two trials). They so far have proven safe [Iffland K. et al. (2017)] and showed beneficial 
effect in reducing convulsive seizures for Dravet syndrome in children. The double-blind study included 
120 children randomly assigned into placebo or CBD cohorts. It showed that 43% of patients taking 
Epidiolex® experienced a 50% decrease in convulsive seizures against 24% for placebo patients [Devinsky 
O. et al. (2017)]. The drug Sativex®(Nabiximols), a 1:1 formulation of CBD and THC applied as oromucosal 
spray, has been trialed for symptomatic relief of multiple sclerosis spasticity and chronic cancer pain [Fallon 
M. T. et al. (2017)]. The latest study published early 2018 was a Phase III, placebo controlled, double 
blinded study, randomly allocating patients to self-titrated CBD/Nabiximols (n=199) or placebo (n=198) 
[Lichtman A. H. et al. (2018)]. The recruited patients were diagnosed with advanced cancers and 
experienced chronic pain that optimized opioid therapy failed to relieve. Considering the primary efficacy 
endpoint, CBD failed to show superior effect to placebo. However, CBD showed a significant advantage to 
placebo in US patients who received lower opioid doses. Pain associated TRP receptors have been 
extensively studied as modulable targets for anti-nociceptive therapy [McEntire D. M. et al. (2016)] and 
[Pecze L. et al. (2017)], and TRPV1, TRPV3, TRPA1 antagonists have entered clinical trials as analgesics 
candidates [Kaneko Y. et al. (2017)].  Studies of vanilloids effect on TRP channels have been documented 
not only as analgesics [Lindvall O. et al. (2009)] but also as multitarget agents affecting pathways of 
inflammation, metabolism, and death. Anti-tumorigenic potential of vanilloids is of particular interest and 
CBD is currently one of the most studied vanilloids for peripheral and CNS disorders [Scuderi C. et al. 
(2009)], [Hill A. J. et al. (2012)], [Morales P. et al. (2017)], and [Morales P. and Reggio P. H. et al. (2017)]. 
For glioma, CBD was described as an agonist to TRPV2 channels and sensitized tumor cells to in vitro 
cytotoxic effect of TMZ, BCNU or doxorubicin [Nabissi M. et al. (2013)]. Combination therapy of THC 
and CBD have also been investigated and showed these two vanilloids acting via distinct signaling pathways 
yet inducing synergistic reduction in glioma viability [Marcu J. P. et al. (2011)] and [Torres S. et al. (2011)]. 
These promising in vitro and pre-clinical in vivo data fueled the initiation of Phase II clinical trials of 
Sativex® in combination with first line therapeutic agent TMZ (Temodar) for the treatment of recurrent 
GBMs. The study showed positive results for patients receiving Sativex® (83% one-year survival rate) 
against 53% for placebo treated patients [GW Pharmaceuticals communications Feb 07, 2017]. To ensure 
success throughout other phases of the trials, it will be necessary to apply robust stratification strategies 
during trial enrollment. A good example of trial success is the current first line therapeutics TMZ where 
good segregation of drug sensitive and inert tumors was clearly established, with TMZ sensitivity associated 
with active mismatch repair (MMR) and resistance associated with overexpression of MGMT and/or 
insufficient DNA repair [Lee S. Y. (2016)]. In our study, we engineered mouse models of glioma based on 
established genetic alterations of different human GBM subtypes [Brennan C. W. et al. (2013)] and [Plaisier 
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C. L. et al. (2016)]. Genetic alterations have previously been proposed for survival prognostics. Indeed, 
Purkait et al. recently proposed a classification of IDHwt GBMs into three prognostic subtypes based on 
their teleomerase reverse transcriptase (TERT) and O (6)-methyl guanine methyltransferase (MGMT) 
promoter methylation status and that regardless of other genetic alterations [Purkait S. et al. (2016)]. Using 
our in vitro cytotoxicity screening data, we proposed a stratification strategy based on sets of genetic 
alterations that indicate prospective good-CBD responders. We also uncovered basal ROS levels as potential 
biomarker of CBD sensitivity. The method we developed is fast and easy to carry out and needs small GBM 
tumor biopsies. Therefore, prospective CBD responders could be identified within hours the same day and 
therapeutic decision taken accordingly.  
6. Summary 
To mimic the genetic diversity of human GBMs, we genetically engineered mouse glioma models to express 
sets of tumor suppressor deficiencies and overactive proto-oncogenes that have been associated with 
different human GBM subtypes. There, we created a simple tool to study the effect of few key genes on 
glioma genesis, evolution, and their role in sensitizing to potential therapeutics. The effect of NPCwt 
conditioned medium was evaluated on a selection of our mouse glioma models and we showed 
endovanilloids exerting cytotoxicity in gliomas of different genetic backgrounds. We then tested the effect 
of plant-derived vanilloid CBD not only on the generated mouse gliomas, but also on a collection of 21 
patient-derived GBMs and found CBD inducing GBM death to different extent. We classified GBMs into 
prospective good- and low-CBD responders. We validated our in vitro cytotoxicity screen by in vivo therapy 
studies comparing the effect of CBD in prospective low- and good-CBD responders. There, only the 
prospective good-CBD responders benefited from CBD therapy in the form of prolonged survival. We 
characterized the cell death mode induced by CBD in human GBMs as being apoptosis in p53wt GBMs or 
autophagy in p53 mutant GBMs. Upon treatment, levels of water-soluble ROS systematically decreased in 
mouse and human GBMs regardless of their sensitivity to CBD while mitochondria-specific ROS 
(MitoSOX) were increased only in good-CBD responders. Although CBD can be considered having an 
antioxidant effect on GBMs, we revealed that not all antioxidants are beneficial in CBD therapy. Screening 
for combination therapeutics to potentiate CBD effect, we found NAC increasing CBD effect while EGCG 
decreased induced cytotoxicity. We revealed NFkB-p65 as indispensable in CBD induced GBM death in an 
established proneural mouse glioma model of p65 loss. We showed that CBD increases NFkB-p65 nuclear 
translocation in good-CBD responders while it tended to decrease sometimes already high nuclear 
accumulations of p65 in low-CBD responders. Further investigations to uncover the functional importance 
of nuclear p65 revealed that although CBD induces nuclear translocation of p65, it does not activate NFkB 
transcriptional activity and would decrease TNFα induced activation, only in good-CBD responders. In low-
CBD responders, we were however unable to induce promoter activity even with TNFα.  As NFkB and 
NRF2 pathways are two co-regulated arms in oxidative stress, we evaluated the status of NRF2/ARE activity 
comparing a low- to a good-CBD responder at basal levels. To the contrary of the good-responder, the low-
responder displayed high NRF2/ARE pathway activation. After CBD treatment, levels of NRF2 pathway 
activation increased in both GBMs with the most increase observed in the good-responder. Our study is 
well-suited in the personalized medicine era as we proposed two approaches to help in predicting CBD 
therapy outcome in GBM patients. In the first one we highlighted sets of genetic alterations that sensitized 
GBMs to CBD in our cytotoxicity screens (e.g. loss or mutation in cdkn2a and EGFRvIII overexpression, 
hot spot p53mutant and PDGFB overexpression). The second method proposed to use a metabolic approach 
to predict CBD response. Indeed, in vitro, we showed that water soluble ROS levels inversely correlate with 
the propensity of GBMs to respond to CBD. In a pre-clinical setting, we showed that GBM biopsies of 
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prospective low- and good-CBD responders could be identified based on their ROS levels without any drug 
treatment: the lower the ROS levels, the higher the sensitivity to CBD. Further investigation of this 
straightforward method using larger panels of GBMs will be needed to apply this prognostic tool in clinical 
practice. 
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